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Abstract 
 
Breast cancer is the most commonly diagnosed cancer among U.S women, besides skin cancer. 
More than 1 in 4 cancers among women are breast cancer. And though death rates have been 
decreasing since 1990, about 40,170 women in the U.S. were expected to die in 2009 from breast 
cancer.  
 
The progress of molecular profiling, in the last decade has revolutionized the understanding of 
cancer, but also introduced more complexity with new data such as gene expression, copy 
number variation, mutations and DNA methylation. These new data open up the possibility of 
differential diagnosis, much more precise prognosis as well as prediction of therapy response 
than any of the diagnostic tools that are available in the current practice. Additionally, 
epidemiological databases store clinically relevant information on hundreds of thousands of 
patients. However, with the abundance of all this information, clinicians will need new tools to 
access and visualize such data and use the information gained to treat new patients. The general 
problem will be to access, filter and analyze the data and then visualize them in a clinical 
context. This data ranges from clinico-pathological information, to molecular profiles from high-
throughput genomic measurements and imaging data. Furthermore, data from patient 
populations is aggregated on epidemiological level and can be found under numerous clinical 
studies.  
 
The goal of this masters’ thesis is to develop tools that enable handling, combining and 
visualizing multiple molecular and epidemiological data types in the context of a clinical 
application for breast cancer and include them in a demonstrator that will showcase the 
approach.  
 
This platform will cover several classes of tools: 1) Tools for visualizing data from different 
molecular modalities 2) Visualizing epidemiological data, 3) Case based reasoning that will 
compare the data of a current patient with a collection of data from previous cases or analyze the 
specific data of a patient with the aid of combining available multiple data types. 4) Filtering and 
organizing tools for clinical trials, which present the clinical trials relevant to the patient under 
treatment clearly and in a more user-intuitive manner. Additionally, we will explore ways to 
generalize these tools to datasets from ovarian cancer and possibly other diseases.
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Chapter One: Introduction 
In time of rising data transfer rates, increasing storage capabilities and generation of new data 
from sensors, computers, cameras, phones, etc. more and more data is produced and needs to be 
handled. This trend is not limited to one specific field, rather it ranges from the personal data 
such as picture and music collections, up to the huge amounts of data generated by enterprises. 
Companies like the retail giant Wal-Mart handle more than one million customer transactions 
every hour, feeding databases estimated at more than 2.5 petabytes. The social-networking 
website Facebook is home to 40 billion photos its members uploaded. Furthermore, research 
facilities like CERN, Europe’s particle-physics laboratory, during their experiments at their 
Large Hadron Collider, generates 40 terabytes of data every second. 
This data offers great new opportunities, but it also leads to new challenges in making this data 
useable. 
 
1.1. Data Overload in Medicine 
In the last few decades, there have been rapid strides in medicine with the invention of new 
technologies and a greater understanding of human biology. New diseases and challenges in 
managing existing diseases have driven a continuous development of new diagnostic and therapy 
methods taking advantage of developments in all branches of science and technology. However, 
the use of advanced technologies is also changing clinical practice. The paper-based files used to 
document patient medical data have given way to digitally recorded and centralized electronic 
health record (eHR), easily accessible from everywhere. We have progressed from imaging data 
developed from single-layered X-ray images to digital computerized tomography (CT) and 
magnetic resonance imaging (MRT) that create three-dimensional views of the human body. 
More effective methods and higher resolutions are making these images increasingly detailed. 
New developments in the clinic have also been driven by advances in high-resolution molecular 
profiling. The human genome was first sequenced in 2001, new high-throughput technologies 
were developed to profile DNA, RNA and epigenomic profiles of samples, all which created a 
new opportunity to understand the human organism in a completely new way. In the last decades 
these developments have lead towards development of new molecular diagnostic tools, which 
have already advanced our understanding of cancer and other diseases. 
However, even a basic output of sequencing of a personal genome already contains ca. three 
billion base-pairs of the human DNA. And this data is extended by additional technologies like 
the molecular profiling, mentioned before. This adds new data types like gene expression, copy 
number variation, mutations and DNA methylation to the already available data used in the 
medicine.   
           Chapter One: Introduction   
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All of these technologies are creating huge amounts of new and complex data that carries great 
potential. They provide possibilities of differential diagnosis, accurate prognosis as well as 
prediction of therapy responses than any of the diagnostic tools that were available before. But 
they also create new challenges like the accessing and handling of this data that need to be 
solved 
 
Figure 1: Growing sizes of medical data. 
1.2. Data Visualization as a Solution 
„A picture is worth a thousand words.“  
This phrase illustrates the advantages of a common method of information processing that 
humans have used time and time again - „information visualization“. Maps from ancient Egypt, 
the geometry diagrams of Euclid and the statistical diagrams of Playfair are only a few examples 
in which information is presented in a visual way to support its understanding by the human 
mind. The idea behind this technique may have remained the same, but with the development of 
new technologies, the art of visualization has been developing continuously. They are no longer 
static pictures of a single data set. Today visualizations can be prepared automatically at time of 
use, can be made dynamic and interactive, and can be integrated into a larger process of decision 
making.  
Questions that are too difficult to be answered purely mentally can be analyzed and solved with 
the help of visualizations. The use of rapid access to large amounts of data, and the fact that they 
analyze and process data faster and with accuracy higher than humans could ever do, make them 
to a technology with a great potential in handling the data overload of our time. 
Visualizations follow a basic processing of data consisting of four parts, shown in Figure 2: 
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Figure 2: The process of data visualization in four basic parts. 
• The data that includes the knowledge of the visualization 
• A preprocessing and transformation part that transformers the data into a form the 
visualization can display 
• The visualization itself that presents the processed data and represents the interface to 
the human 
• The human that analyzes and processes the cognitive information.   
 
1.3. Project Context 
This thesis is the result of a collaboration between the University of Heidelberg, Germany and 
Philips Research North America. It originated as part of a research project of the department of 
Ultrasound, Photonics and Bioinformatics of Philips Research working in the area of clinical 
decision support. This team has focused on analysis and clinical application of molecular 
profiling and other data in the context of breast and ovarian cancer. Their experience with a 
variety of data types and the implication of their analysis in the clinic was the base from which 
the topic for this thesis emerged: „Design and implementation of prototypes that use 
visualization technologies to access and handle multiple medical data types for breast cancer 
decision support.“ 
In more detail, we used different visualization methods and technologies like maps and charts to 
create self-contained tools that can present a multiplicity of medical data types. Each tool also 
provides interfaces that make the communication and interaction between them possible. To 
show the benefits of those interactive tools, we included them in a demonstrator that showcases 
this approach. 
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The thesis includes a theoretical part as well as a practical part.  
In chapter 2 we evaluate data overload in medicine based on the available literature on the 
subject. In addition, we interviewed clinicians from the University of Heidelberg to obtain better 
understanding of the needs and requirements for data visualization in oncology.  
Chapter 3 describes the requirements for the project as well as the technologies and architecture 
we’re using for the development. 
Chapter 4 describes the actual development process in detail. It describes the motivation and 
specifications as well as the implementation and the issues and challenges for each tool.  
In chapter 5 we evaluate our results by presenting the demonstrator to the same clinicians we 
interviewed earlier to obtain feedback on the implemented prototype. As a follow up evaluation 
step we describe two new tools, which were build on the components developed in the course of 
the thesis. 
In chapter 6 and chapter 7 we discuss the advantages and disadvantages we identified in this 
thesis and end with a conclusion. 
14 
Chapter Two: Methods 
Data overload has been discussed in industry as well as in medicine. There are many 
publications written about the problem of data/information overload and equally as many 
publications proposing solutions to handle this overload. Here we present an overview of the 
literature we used to understand data overload in medicine and about the idea of visualizations as 
a solution of this problem. Furthermore, we describe interviews with physicians, which provided 
information about the requirements and the needs they have and to validate the ideas we 
obtained from the literature. The result of this was a number of use-cases for several data types, 
which served as templates for the later implementation. 
 
2.1. Literature Survey 
The focus of this thesis covers two specific fields, data overload in medicine, especially in breast 
cancer treatment, and data visualization as one way to handle this overload. We begin by 
reviewing the extensive literature that has been written about data overload in clinical field. This 
is needed to evaluate the approach of data overload in medicine and also to find medical 
datatypes that afflicted by this overload. We then turn to the literature and research that has been 
written about visualization technologies. The goal of reviewing the literature is define the scope 
of work: the relevant medical datatypes, the ideas, and the concepts of visualization. 
 
The first question we have to be clear about is: „Do we have medical data types that consists of 
huge amounts of data that need to be supported by computer systems?“ As a starting point the 
book „Biomedical Informatics for Cancer Research“ from M.F. Ochs et al.[1] reviews the work 
from a number of researchers who have produced open source software addressing the need for 
data management, integration, analysis, and visualization to aid cancer research. It provides a 
good overview of the use of data in cancer research. It highlights the advent in genomics and 
clinical trials as main producer of clinical data in the last decades. Molecular data is defined as 
one of the most important data source in the future which will revolutionize the treatment of 
cancer patients [2; 3]. Other projects already tried to use this new type of data to create decision 
support systems like the Caleydo framework [4].  
Another type of data that use for decision support is underestimated is the epidemiological data. 
This data is stored in large epidemiological databases like the Surveillance Epidemiology and 
End Results (SEER) database [5] which currently contains over 800.000 records. Only a handful 
of tools have used this data, which actually has high potential in supporting physicians with 
statistical information. One of these tools is Adjuvant! Online [6], which utilized the SEER 
database to help physicians and patients to select therapy and understand the risks and benefits 
of getting additional therapies after surgery.  
A typical data source that is used in the clinical work all the time is the clinical literature in form 
of books and articles. But the amount of new publications is increasing very rapidly. Databases 
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like the PubMed database [7] contain references to more than 16 million articles in some 4800 
biomedical journals [8]. To access this information effectively, new clinical tools are necessary.  
The four data types mentioned in the literature before have similar characteristics: they are 
stored in large databases, several data sources are available for every data type, each of the data 
types could benefit from visualizations and in this way avoid the increasing of the data overload 
in the clinic. For that reason we decided to focus our efforts in finding visual solutions for these 
types (overview in Table 1). 
 
Data Type Clinical Need Use Example 
Epidemiological Data Population based Studies, 
Population Statistics, 
Decision making tools 
SEER Database is used to 
drive „Adjuvant! Online“, 
widely used tool in Breast 
Cancer Oncology 
Molecular Data Molecular Profiling CGI - a 97-gene measure of 
histological tumor grade 
Clinical Trials Information Trials as basic mechanism of 
discovery in clinic 
Therapy Decisions,  
Enroll patients in trials 
Clinical Literature Dissemination of Knowledge Cancer Biology, 
Drug Information, 
Study Reports, etc. 
Table 1: Data types and their use in medicine. 
Before creating data visualizations, we need to understand the types of visualizations in 
existence and the information they can present. David McCandless provides a good first 
overview about available visualizations in his book „The Visual Miscellaneum: A Colorful 
Guide to the World's Most Consequential Trivia“[9], in which he uses graphs, charts and 
illustrations to visualize relationships and compelling data. A deeper insight is given by Chun-
houh Chen’s „Handbook of Data Visualization“[10] and Julie Steeles’ „Beautiful Visualization: 
Looking at Data through the Eyes of Experts“[11], that provides additional types of 
visualizations. They supplement their work with historical information and facts about what is 
needed to make a good visualization as well as the differences between them. 
During this search other projects were found, which are discovering the possibilities of 
visualizations to present medical data, [12-14]. All of them use different visualization types in 
different medical fields to present medical data.  
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2.2. Design Use-Cases 
Based on the information about the data types and the visualization techniques collected from 
the literature, we created use-cases for a number of clinical scenarios. In this chapter the 
different use-cases are presented and explained in detail. 
 
2.2.1. Epidemiological Data 
The epidemiological data is used as input to two different tool types. In the first tool statistical 
information about the occurrence of cancer in the population are shown in form of pie charts. 
These charts display for example the distribution of breast cancer patients over different age 
groups or stages. The data of the current patient is automatically highlighted in the particular 
chart.  
The second tool uses the data to show survival curves of selected population groups. In this way 
the effects of different therapies, the advancing ages or other attributes can be compared.  
To create an intuitive interface the pie charts of the first tool are used as selection panel for the 
survival tool. By selecting different slices of the charts a query can be generated which can be 
used to specify the population group used to create the curves. The design of this use-case is 
shown in Figure 3. 
 
 
Figure 3: Use-case for the epidemiological data. 
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2.2.2. Molecular Data 
The molecular data is used to present biological pathways, which are relevant to a patient. A 
pathway can be selected and is shown in its original version on the left side of the screen. This 
pathway now can be analyzed, which means the patients molecular data is compared with the 
original pathway data and presented on the right side of the screen. This modified pathway will 
highlight any differences from the original pathway by changing the color of missing or 
additional molecules. If a molecule is missing the effects are shown at the connections to other 
molecules. In this case the lines that connect the molecules are drawn thinner or thicker and in 
red or green depending whether they are inhibiting or activating. Additionally there is a 
perturbation score that shows the significance of the pathway deregulation. The design of this 
use-case is shown in Figure 4. 
 
 
Figure 4: Use-case for the molecular data. 
 
2.2.3. Clinical Trials 
The data from the clinical trials is used in a search tool that positions the locations of the 
particular trial on a geographical map. It’s possible to filter the results by specifying the state and 
country in which the trial should be and by choosing the status open or closed. For each result 
the tool creates a marker on the map which includes the information of the trial like title, 
description and so on. The map itself contains control elements to move around and to zoom in 
and out. The design of this use-case is shown in Figure 5. 
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Figure 5: Use-case for the clinical trial data. 
2.2.4. Literature 
Medical literature serves as input for an interactive search tool. The tool offers several filter 
options to specify the search such as keywords, publication language, etc. The literature search 
can be accessed from any other tool and would start the search automatically if a start value is 
transmitted. 
Furthermore the results of the literature search can be used as input for a summarizing tool that 
presents the keywords in form of a Word Cloud. In this visualization type the keywords are 
shown in different font sizes depending on their occurrence in the text. The higher the 
occurrence the larger the font size. The Word Cloud is also interactive so that the user can click 
the shown words to start automatically a new search. The designs for the two use-cases are 
shown in Figure 6 and 7. 
     
Figure 6: Use-case for the literature search.                    Figure 7: Use-case for the word cloud. 
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2.3. Interviews with Clinicians 
The cooperation between clinicians and software developers is essential in the development 
process for useful and intuitive applications. Without including the end-user into the 
development process it’s almost impossible to create software that fits their requirements and 
needs. Providing solutions that meet the user requirements is the key to deliver a useful product 
that will be accepted. For that reason, we contacted oncologists who were interested in the 
problems our project addressed. Three oncologists of the University Hospital of Heidelberg 
kindly agreed to talk to us.  
These are: 
• Dr. Clemens Stockklausner, physician at the Pediatric Clinic of the University Hospital 
of Heidelberg, working in the field of children oncology. 
• Dr. Jörg Heil, assistant physician at the Women Hospital of the University Hospital of 
Heidelberg, working in the fields of mamma carcinoma, diagnostic, surgery and system 
therapy. 
• Dr. Florian Schütz, senior physician at the Women Hospital Salem that is in cooperation 
with the University Hospital of Heidelberg. He is the vice-chairman of the hospital and 
reasonable for the whole field of the gynecology and perinatology working in the 
medical fields of the gynecological oncology and perinatal medicine.  
 
The interviews were divided into three parts, a general part, a prototype presentation and a 
discussion. 
The general part contained questions about the data types their using in their daily workflow, 
tools their already using and wishes they would have for new software.  
After these general questions we presented three PowerPoint scenarios of possible workflows to 
them. These scenarios were built from the use-cases described in chapter 2.2 and show possible 
processes of the tools and the transitions between them. They served us to explain the physicians 
our ideas and to get feedback what is good or what they would change. The complete scenarios 
are presented in Appendix A. 
Finally, we asked them about their impressions and what they think about our concepts in 
general. (A complete flow of the interview is given in Figure 8.) 
All physicians agreed with the statements of very fast growing data in medicine and with very 
high potential in software that supports them with a better use of this data. Currently the only 
software that finds use in the work of the physicians, is the decision support tool Adjuvant! 
Online. They agree with the data types discussed in the literature, but they were divided in their 
wishes for the presented tools. They see the use of some of the tools not only in decision support 
for themselves, but more in helping their patients to understand what choices they have and what 
the consequences are. Another important field the tools could be helpful is in scientific research. 
Access to published literature for example doesn’t find the biggest use in patient care, because 
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therapies have to follow strict guidelines, but in answering scientific questions or supporting the 
physician with the newest studies helping him to stay up to date.  
In the following section we summarize the physicians opinions and suggestions to each of the 
tools in the scenarios. 
 
Visual Query Builder in combination with Survival Curve Manager 
• Intuitive, fast and easy to use 
• Useful for physicians with less experiences, given that experienced physicians are 
intimately familiar with these statistics. 
• Particular interesting if statistics incorporate different therapy choices. 
 
Biological Pathway Visualizer 
• Big potential and will be very important in future. 
• Very future-oriented. Will definitely come but may take another several years for such 
data to be used routinely in the clinic.  
 
Geographical Trial Finder 
• May not be very useful for physicians in Germany, because usually physicians typically 
refer to their own studies or the studies of their colleagues. 
• Bigger use for patients who are interested in what and where studies are available. 
 
Literature Search and Word Cloud 
• Usually, literature searches aren‘t used in patient care. Exceptions are very uncommon 
cases. 
• High potential in scientific research 
• Good filtering options, but would need additional options, e.g. Patient age, gender, etc. 
• Text Summarizing tools like the Word Cloud are nice gadgets but may not be practical 
for use in patient care. Possibly use as an quick overview in a research application.   
 
In the last part of the interviews we asked the physicians about their general impressions and 
feelings of these tools.  
They like the way of visualizing large amounts of data and see high potential in these types of 
tools. They also appreciated the automatic functions, the interaction between the tools and the 
intuitive user interface seems to be helpful in making their work easier.  
Transcripts of the complete interviews are in Appendix B.    
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Figure 8: The flow of the interview. 
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Chapter Three: Technical Details 
 
3.1. Requirements 
The requirements for this project were built out of the literature research and the interviews. 
They combine the wishes of the physicians as well as the technological features we want to 
include. The key requirements for our prototype were: 
• Accessible from everywhere 
• Intuitive User Interface  
• Consistent User Interface. UI elements should be ordered in the same way in every tool. 
This guarantees a high usability. 
• Easy integration into other applications 
• Modular expandable, easily changeable. It should be simple to integrate tools into the 
platform as well as it should be possible to change or remove tools that aren’t needed.  
• Performance, very large datasets are used. 
• Minimal system restrictions, software must be fully working on any available systems. 
 
3.2. Technologies 
The selection of the right technology for the task is one of the critical points in software 
engineering. The complete project depends on the technology that is used. The technology 
defines what is realizable and what isn’t.  
After discussing the requirements of Chapter 3.1 we decided to develop our tools in form of a 
web platform. Web Platforms have several advantages to typical Desktop Applications. They are 
accessible from every system with internet access, running out of standard web browsers which 
available on every computer. Typically, web-based applications have almost no system 
restrictions.  
Therefore, we needed a web technology that will provide the functionalities suitable based on 
the requirements, to receive data from databases and other web services and for the creation of 
visualizations. In the next sections we’re introducing four modern web technologies, compare 
them and elaborate on the rationale for our choice.  
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3.2.1. HTML5 
The World Wide Web’s markup language has ever been HTML (HyperText Markup Language). 
It was primarily designed to describe scientific documents, but over the years the language has 
continued to develop and learned to describe a lot of new types of documents. The main area that 
has not been adequately explored is the area around the so called „Web Applications“. HTML5 
[15], the newest major revision, attempts to rectify this by developing new specifications. In 
particular, HTML5 adds many new features like <video>, <audio> and <canvas> elements 
which are designed to improve the inclusion and handling of multimedia and graphic content as 
well as other new elements such as <section>, <article>, and <header> that improve the 
semantic richness of documents. At the moment HTML5 is still under development, what means 
that still not all functions are fully available and not all bugs are fixed. But the progress is very 
fast and also appearing problems are fixed very quickly.  
In this project we’re interested in the <canvas> element, since it provides the possibility for 
dynamic, scriptable rendering of 2D Shapes and bitmap images. The canvas element is a 
drawable region defined in HTML code with a height and width. It can be placed at any point in 
a HTML document. JavaScript provides functions to get access to this canvas element and also 
provides a full set of drawing functions similar to other common 2D APIs, which allows 
generating dynamical graphics. Canvas only supports one primitive shape - rectangles. All other 
shapes must be created by combining one or more paths. There is a collection of path drawing 
functions which make it possible to compose very complex shapes, but the effort to create such a 
shape is very high. 
Figure 9 shows a simple graphic which is created by using paths. This example also shows that 
the complete coding is done in JavaScript and is only be drawn into the canvas element. 
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Code: 
<html> 
 <head> 
  <script type="application/javascript"> 
    function draw() { 
      var canvas = document.getElementById("canvas"); 
      if (canvas.getContext) { 
        var ctx = canvas.getContext("2d"); 
        ctx.beginPath(); 
        ctx.arc(75,75,50,0,Math.PI*2,true); // Outer circle 
        ctx.moveTo(110,75); 
        ctx.arc(75,75,35,0,Math.PI,false);   // Mouth (clockwise) 
        ctx.moveTo(65,65); 
        ctx.arc(60,65,5,0,Math.PI*2,true);  // Left eye 
        ctx.moveTo(95,65); 
        ctx.arc(90,65,5,0,Math.PI*2,true);  // Right eye 
        ctx.stroke(); 
      } 
  } 
  </script> 
 </head> 
 <body onload="draw();"> 
   <canvas id="canvas" width="150" height="150"></canvas> 
 </body> 
</html> 
 
Figure 9: Simple Graphic generated with paths. 
 
Advantages 
• Minimal learning curve since most people already know the basics of HTML 
• Large pool of developers 
• Supported natively by the web browser (Currently not all functions are supported in 
every browser) 
• Does not require any installation of third party software 
Disadvantages   
• No predefined widgets like panels or dialogue boxes.  
• Javascript underlies the Same Origin Policy (SOP). This policy permits scripts running 
on pages originating from the same site, but prevents access to methods and properties 
across pages on different sites. Makes the access to external data very complicated 
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3.2.2. Protovis 
Protovis [16] is a free and open-source project of the Stanford Visualization Group. It’s a very 
powerful graphical toolkit that uses JavaScript and SVG to build web-native visualizations. Part 
of what makes it special is that, because it’s written in JavaScript, don’t need any plugin to run 
in the browser. Protovis is especially developed for designing visualizations. In this way, it uses 
some of the simplicities and low-level controls of graphical systems by dealing directly with 
graphical elements but specifies marks declaratively as encodings of data. Figure 10. shows this 
way of declarative programming and how easy it is to create an attractive chart. In the paper 
„Protovis: A Graphical Toolkit for Visualization“, Michael Bostock and Jeffrey Heer [17] write 
in more detail about the motivation and idea behind Protovis and the benefits of Protovis 
compared to other graphical toolkits. 
 
Code: 
var vis = new pv.Panel().width(150).height(140) 
    .add(pv.Bar) 
       .data([1, 1.2, 1.7, 1.5, .7, .2]) 
        .bottom(0).width(20) 
        .height(function(d) d * 80) 
        .left(function() this.index * 25) 
    .root.render(); 
 
Figure 10: Bar Chart generated with Protovis. 
 
Advantages 
• Fast in building small charts 
• No additional plugins required 
• Can handle datasets with more than 10.000 data points 
Disadvantages 
• Code gets very complex for bigger charts 
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3.2.3. Processing 
Processing [18] is an open-source programming language and environment especially for 
creating images, animations and interactions. The developers wanted a means to „sketch“ ideas 
in code. Originally built as a domain-specific extension to Java for artists and designers, 
Processing evolved into a full-blown design and prototyping tool used for large-scale installation 
work, motion graphics and complex data visualization. Processing itself is based on Java but 
because its kept fairly simple it supports only few libraries of the Java API. Figure 11 shows an 
applet with a static pie chart that uses a set of data points, stored in an array.  
 
Code: 
size(200, 200); 
background(100); 
smooth(); 
noStroke(); 
float diameter = min(width, height) * 0.75; 
int[] angs = [30, 10, 45, 35, 60, 38, 75, 67]; 
float lastAng = 0; 
for (int i = 0; i < angs.length; i++)[] 
  fill(angs[i] * 3.0); 
  arc(width/2, height/2, diameter, diameter, lastAng, 
lastAng        + radians(angs[i])); 
  lastAng += radians(angs[i]);   
} 
 
    
 
Figure 11: Pie Chart generated with Processing. 
 
Advantages 
• Many additional libraries available 
• Easy to generate 
Disadvantages 
• Java required 
• Applets are slow especially for bigger amounts of data points 
• Very strict restrictions for external data access 
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3.2.4. InfoVis 
The JavaScript InfoVis toolkit [19] is, like the name says, completely based on JavaScript and 
provides tools for creating interactive data visualizations for the web. Because of its JavaScript 
programming It is easy to integrate into other web applications. With release 2.0 the number of 
new visualization types has doubled. There are simple visualizations like Bar Charts and Column 
Charts up to very complex visualizations like Tree Maps and Graphs. It also includes very 
special visualizations like the Sunburst, shown in Figure 12. or the Icicle. As input for the graphs 
the toolkit uses only JSON (JavaScript Object Notation) Objects [20]. JSON is a lightweight 
data-interchange format that is easy to read and write for humans. It is similar to XML but 
reduces the necessary chars to a minimum. JSON objects only consist of simple, unordered 
name/value pairs.    
 
 
Figure 12: Sunburst generated with InfoVis. 
Advantages 
• Many complex visualizations 
• Fast loading 
• Fast in building 
• Easy to integrate in other web applications because of JavaScript 
Disadvantages 
• Only JSON as Input allowed 
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3.2.5. Google Web Toolkit 
The Google Web Toolkit (GWT) [21] is a development toolkit for developing and optimizing 
complex browser-based applications. It provides the developer with a huge collection of 
development tools, programming utilities and widgets that make the creation of Rich Internet 
Applications (RIA) totally different to other frameworks. The biggest difference to other web 
technologies is the use of Java to realize the browser-side code instead of JavaScript. The main 
problem of Rich Internet Applications is the ever increasing size and complexity that is very 
difficult to manage. Java was designed to make managing those large applications easier. While 
bringing all of Java’s benefits to Rich Internet Applications there are still methods to integrate 
and communicate with JavaScript code. Means you can use your old code as well as third-party 
libraries that are written in JavaScript.  
At the core of GWT is a Java-To-JavaScript compiler that produces optimized code capable of 
running on all modern browsers, like Internet Explorer, Firefox, Mozilla, Safari and Opera.  
Beyond this compiler GWT includes a large library of widgets and panels that makes it easy to 
create full web application that looks more like desktop applications. This library includes 
simple elements like textfields, buttons, drop down menus and other form fields. In addition, it 
includes more complex widgets including menu bars, dialog boxes, tab panels and others. Figure 
13. shows a demo mail application completely created with GWT including panels, trees, lists 
and buttons. 
 
Figure 13: Demo Mail Application created with GWT. 
 
But there are also additional libraries that aren’t included in the standard package, like the 
Visualization API which is of special interest in this project. This API provides methods and 
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interfaces to communicate between data sources and visualizations. GWT itself includes only a 
basic set of charts like pie charts, bar charts and column charts. More advanced visualizations 
like graphical networks or tree maps are currently not included. But with the advantages of the 
tight JavaScript communication it’s possible to integrate third-party libraries to use every chart 
needed. More information and a good starting-point for working with GWT is the book „GWT 
in Action“ from Robert Hanson and Adam Tacy [22] 
 
Advantages 
• Java-to-JavaScript Compiler 
• Simple programming of complex Rich Internet Applications 
• Large library of panels and widgets  
Disadvantages 
• Debugging the compiled JavaScript code is practically impossible 
 
 
3.2.6. Technology Discussion 
The key differences between the technologies discussed in the previous sections, is the purpose 
they are developed for. Protovis, Processing and InfoVis are languages purposed for creation of 
graphics, such as charts and images. In this field the possibilities cover a wide range, from a 
simple 2D image to a complete interactive 3D animation. But for the purpose of building 
complete web applications this toolkits aren’t the best choice. In first attempts we used these 
technologies to create prototypes for visualizing survival curves (Chapter 2.2.1) to discover 
which technology covers best our requirements. During these developments it turned out that 
building graphs is very simple but integrating other components such as buttons and windows 
isn’t provided. Every component must be created by drawing single elements. This cost much 
time and lowers the performance. 
This is where HTML5 and GWT provide a better solution. Both are made for creating complete, 
interactive websites. In HTML5 the most of the structure must be coded manually, but like 
GWT, it supports a full set of predefined panels and widgets, which makes implementing faster 
and easier. Also both support the generation of visualizations. HTML5 with the canvas element, 
where the individual graphics must be drawn manually with basic shapes and paths, and GWT 
with its basic set of visualizations that can be integrated. One must take note that HTML5 as 
GWT aren’t made for visualizing data. Especially, large amounts of data and complex 
visualizations, both technologies are reaching their limits. This is where Protovis, Processing and 
InfoVis have their advantage. A summarizing of all pros and cons is shown in Table 2. 
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Technology Advantages Disadvantages 
HTML5 • Common web language 
• Large pool of developers 
• Natively supported by most web    
browsers 
• No third party software required 
• No predefined widgets  
• Javascript underlies the 
SOP 
Protovis • Fast development of small charts 
• No additional plugins required 
• Can handle large datasets  
• Complex code for big 
charts 
Processing • Many additional libraries available 
• Easy to generate 
• Java required 
• Slow 
• Restrictions for external 
data access 
InfoVis • Many complex visualizations 
• Fast loading 
• Fast in building 
• Easy integration possibilities 
• Only JSON as input 
GWT • Java-to-JavaScript Compiler 
• Simple programming of complex 
RIAs 
• Large library of panels and widgets  
• Difficult debugging after 
compiling 
Table 2: Summary of pros and cons of the technologies. 
Both technology groups have their own advantages and disadvantages. So our choice was to mix 
the technologies to get the best sides of both. The biggest advantage of GWT compared to 
HTML5 is that the predefined components make creation of RIAs very easy and fast. 
Furthermore, GWT provides a much better manageability of large applications. Therefore, we 
decided to use GWT as main programming language that is reasonable for the UI and the 
communication between the client and the backend. Additionally, we extended these UI 
elements by using ExtGWT [23], a Java library that modifies the available components and add 
even more. Since the visualization capabilities of GWT and ExtGWT did not meet our 
requirements, we decided to integrate an additional toolkit to to provide the visualization 
component. We choose InfoVis because of the possible interactions, fast graphics and the simple 
way of generating them, but this is only a personal preference of the author. In the 
implementation we show that it is quite easy to use the GWT visualizations as well as the 
InfoVis graphics, but it is also straightforward to integrate any other visualization technology 
such as Protovis or Processing.   
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Technology Decision 
GWT and ExtGWT  
• Core- Technology  
• Client-Side 
 GWT specific components such as buttons, windows, lists and panels will be used to 
generate an intuitive user interface that will contain the different visualization types. 
 Simple charts like pie charts and columns charts will be also implemented by using 
GWT. 
• Server / Backend 
 The backend will also be implemented in GWT specific Java code but during the 
compiling it’s translated into Java servlets. It will include the interfaces between the 
application and the data sources as well as the application logic which will transform the 
plain data into a format the tools can visualize. 
• Client-Server Communication 
 The communication between client and backend will be done by GWT RPC (Remote 
Procedure Calls), which makes it easy to pass Java objects back and forth over HTTP. 
  
InfoVis 
• More complex visualizations 
• InfoVis is offering many new interactive visualization types such as SpaceTrees, 
ForceDirected Graphs, TreeMaps, Pie and Column Charts. For the first implementation 
of the tools the SpaceTrees will be used to visualize the biological pathways. 
 
 
3.3. System Design 
In this Chapter the general architecture of the web application as well as the generic design of 
the tools are explained. Both structures need special attention because they are responsible for 
the changeability and expandability of the tools. 
  
3.3.1. Application Architecture 
The general architecture follows the approach of the MVC (Model-View-Controller) Pattern. 
MVC is a modern type of architecture that separates the architecture into three layers.  
The View renders the model into a form the user can interact with. This can be an interface 
element or a simple output. It is possible that multiple views exist for a single model. The Model 
manages and processes the data given from databases and web services. It responds to queries 
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about its state and responds to instructions to change state. The Controller is the communication 
interface between the view and the model. It accepts input from the user and instructs the model 
to perform actions based on this input. On the other side the controller takes the information 
from the model and sends them to the view.    
This type of architecture supports the web application with the functionality of easily 
interchangeable and expandable tools. The data is processed in the model layer and every tool 
can get access to this information by sending a request to the controller. Figure 14 shows this 
architecture but with a special addition, every tool has its own controller in addition to the 
application controller. GWT requires a controller for every view to handle the incoming events. 
This makes the application even more flexible because if we remove a tool, we don’t need to 
change anything on the controller or the backend. If a fired event reaches a tool, the tool handles 
the event and if there is no tool that could handle the event nothing happens. That is a unique 
feature since in other languages an exception occurs if a request doesn’t reach the target.       
 
 
Figure 14: General architecture of the web application. 
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3.3.2. Generic Tool Design 
The exact implementations of the tools can differ from each other in some detail. However, the 
principal design which all tools are following is shown in Figure 15. Every tool accepts as input 
the data of the actual patient and the particular data from databases, the web or local files. The 
patient data is needed for automatic selections, searches and similar things. This makes the work 
more efficient for the physician. The tools consists of a set of UI elements like panels, buttons, 
containers, etc. which supports the physician with different possibilities to interact with the 
tools. The output is defined by the tool and the visualization type. The data can be visualized in 
elements such as pie charts, maps, tables, etc. 
 
 
Figure 15: General architecture of the tools. 
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Chapter Four: Development 
The development of the individual tools is the most time consuming step in the process of 
creating the application. The first and important step of a good implementation is to be clear 
about the purpose of the implementation as well as the characteristics and attributes. In this 
chapter the procedure of developing each of the tools is described in detail. Each tool description 
begins with a clinical scenario which was the motivation for the particular tool, followed by the 
exact specification of the attributes and methods. This specification defines in detail the input 
and output of the tool as well as every function that has to be integrated. The general 
implementation of the tool and special abilities of the tools are then provided followed by the 
issues and challenges that occurred during the development process are discussed. 
Since the tools only reflect the visualization mechanisms of the application we describe in an 
additional section the structure of the backend which is the interface between the data source and 
the visualization. It describes the procedure of processing the data and making them available to 
the tools. Furthermore it explains some special implementation options that are given by the 
GWT.   
 
4.1. Visual Query Builder 
The Visual Query Builder (VQB) is a multifunctional tool. On clinical side it is used to visualize 
statistical occurrences of cancer within specific attributes, for example the patients’ age or 
cancer grade. These statistics are visualized in form of pie charts that show the different values 
of the attribute in form of slices. The patients’ value is automatically highlighted in the chart so 
that the physician directly gets the information about his patient. 
On application side, the tool has an additional feature, makes it working as a Query Builder. The 
Query Builder allows the user to create a query by selecting different values in the pie charts or 
by activating or deactivating complete pie charts. These queries can be used by external tools to 
modify their data or display additional information. 
 
4.1.1. Motivation / Clinical Scenario 
The epidemiology of cancer is the study of cancer specific factors such as cancer incidences, 
mortality and other tumor characteristics to find the cause of cancer and to identify and develop 
improved treatments and therapies. It could be involved directly into therapy decision finding of 
physicians by presenting population based statistics for the current patient to them. For a new 
patient, this information about how frequent or rare the cancer is and the prognosis of the 
patients with a disease most similar to his/her own would be quite beneficial. For the doctor, 
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getting data on the types of treatment available for patients similar to his own maybe useful. 
Furthermore, the given population would reflect the survival outcome of the patient.   
 
4.1.2. Specification 
 
Figure 16: Overview of the Query Builder. 
 
The Visual Query Builder (VQB) has two main functionalities. It is used as presentation tool that 
visualizes epidemiological data in form of charts and it is a query builder which uses the 
interface components to create queries that can be used by external tools. The specifications for 
both functionalities are explained in more detail in this chapter. 
For the presentation part the VQB requires two data sources, population based data from a 
database and the patients’ personal and medical data, for example age, gender, grade, etc. The 
patients’ attributes are typically a subset of the attributes available in the database.  
The interface which presents the epidemiological data is structured very simple and clear. It only 
consists of a set of chart components, whereas not more than three components are shown on the 
main screen. All other components are placed in a smaller version, in a collapsible box on the 
right border of the screen. They’re ordered in a vertical, scrollable row with a pager on the top 
and bottom. In this way only a maximum of five components will be shown at a time the rest can 
be shown by switching the pages. The box can be opened and closed by a toggle button, which is 
also located on the right border. 
Each of the chart components consists of the pie chart itself and a collapsible list to select values 
of the chart, for example to narrow the range of the age from 41-50 years to 45-47 years. This 
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selection box shows all available values for the attribute, so that the user can select one or more 
of them to modify the shown chart. A submit button that confirms the modifications is located at 
the bottom. 
The initial screen shows three charts in the main panel and the remaining in the hidden box. This 
distribution is defined in the programming, but could be implemented as dynamical variable in a 
future version. The order of these charts is alphabetical, which can be changed during runtime 
through Drag’n Drop. 
The creation of queries is the second ability of the VQB. It extents every chart component by a 
checkbox that enables or disables this attribute for the query building process. After a query is 
requested by an external tool, the Query Builder checks the status of all chart components and 
collects all enabled charts. The attribute name (age, gender,…) and the selected value(s) of these 
charts are mapped and stored in a query. This query is sent back to the requester and can be used 
for other visualizations. The possible procedure of generating a query is shown in Figure 17. 
 
The user has three possibilities to interact with the Query Builder: 
• Change the order of the charts by Drag’n Drop 
• Un-/checking the checkbox reasonable for the state of a chart to enabled/disabled  
• Select values in the according list of a chart to change the focus of this chart 
 
 
Figure 17: Flow Chart of the process of building a query. 
 
4.1.3. Implementation 
The user interface of the Visual Query Builder consists of a horizontal main panel and a vertical 
collapsible box that are filled with objects of the class PieChartComponent. Each of these 
objects represents an attribute of the loaded database for which a mapping in the application 
exists. In this case mapping means the connection between a unique identifier in the application 
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and the equivalent attribute in every database. This mapping is realized by model classes. Every 
database that is used needs a new model that maps its attributes to the available identifiers. 
If the attribute is mapped a new component is created. This component consists of a content 
panel that has the attributes’ name as title and a toggle button in the header that changes the state 
of the component between active and inactive. Below the header a collapsible list of the values is 
following as well as the actual visualization. This visualization is a pie chart from the GWT 
Visualization library and includes the pie chart itself, a legend and tool tips. The color of the 
chart is chosen randomly by an additional function of the utility class and changes only the 
brightness within itself. The deactivation of the component makes the list and chart grayed out 
and unclickable. Differing to the specifications the final version doesn’t need a submit button 
because changing the selection of the list automatically effects in a recalculation of the pie chart.  
The collapsible box mentioned at the beginning of the chapter is an instance of the class 
PieChartBox and contains the remaining chart components. It’s located at the right border and 
can be toggled by a button that is located at the same position. The box has the same size than a 
usual chart component. That’s why it includes the remaining charts in a smaller version so that 
more charts can be displayed at the same time.  
  
 
Figure 18: Screenshot of the implemented Query Builder. 
 
4.1.4. Issues and Challenges 
The biggest challenge in implementing the Visual Query Builder was to build it in an intuitive 
and attractive design that includes all the essential functionalities. This was the reason why we 
decided to make a main panel with only three chart components and put the remaining 
components in a separate box. We inhibited any controls like buttons so that the full 
concentration is on the charts.   
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An issue we couldn’t solve completely is the use of Drag’n Drop to modify the order of the 
components. It is possible to change the sorting order within one of the lists, but if we try to put 
a component from one list into the other we face two problems. On one hand the size of the 
components differs and on the other hand the components in the box are implemented in a 
separate class what makes the transfer a lot more difficult. So we decided to deactivate this 
feature in the first release of our project but planning to fix it in one of the next releases.  
Another issue was the use of different databases in different tools. Often the attributes in 
population based databases mean the same but they differ in the naming. So we have the gender 
in one database but sex in another. To solve this problem we build a mapping between the 
databases and our application, described in more detail in Chapter 4.1.3 Implementation. 
 
 
4.2. Survival Curve Manager 
The Survival Curve Manager (SCM) is a presentation tool that interfaces with the Visual Query 
Builder. It presents statistical survival rates of specific population groups in form of survival 
curves whereby each curve shows the percentage of patients that are alive at specific times. Each 
time a patient dies the curve drops.  
The ability to manage multiple survival curves makes it possible to compare the survival data for 
several populations simultaneously. This is done by using the dynamically generated queries of 
the VQB to modify the input data of the Survival Curve Manager. 
4.2.1. Motivation / Clinical Scenario 
Survival Curves have great potential in visualizing the risk to the patient. They show the 
statistical progress of a disease to the physician and the patient. The comparison of several 
curves is even better because it is possible to visualize the differences of different therapies. This 
can help the physician to decide which therapy is possibly the right or it can help to explain to 
the patient why therapies are important and in which way they can help to extend his life. 
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4.2.2. Specification 
 
The Survival Curve Manager is a pure presentation tool, which only includes controls for 
adding, updating and removing curves. For this reason, two input types are required. At first a 
database is needed that contains the statistical information that should be presented. The second 
input is the query coming from the Visual Query Builder (see Chapter 4.1) that filters the data 
before it is used to calculate the individual curves. There are two restrictions that must be 
noticed. The database must contain the attributes survival time and status since they are 
necessary for the calculations and the attributes that are used in the query must be a subset of the 
attributes in the database. 
The interface consists of a control panel that includes the buttons for adding, updating and 
removing as well as the main graph that will present the curves. The graph can manage several 
curves whereas the limit is set to five curves at the same time. Every curve is drawn in a 
different color so that they can be distinguished from another. A legend at the top of the graph 
shows the attributes each curve is filtered. Furthermore the graph shows the actual percentage of 
survival by moving the mouse over a curve.    
As mentioned above the control panel contains options for adding, updating and removing 
curves. When adding or updating a curve, a new query will be requested from the Query Builder 
and included into the calculation process. The update and remove function are requiring a 
selection of a curve before they can be used. This selection can be made by clicking a curve.    
Figure 19: Overview of the Survival Curve Manager. 
           Chapter Four: Development   
 
 
40 
In Figure 20. the procedure from getting a query to displaying the calculated function is drawn 
schematically.  
 
Figure 20: Flow Chart of generating a survival curve. 
 
4.2.3. Implementation 
The user interface of the Survival Curve Manager (SCM) consists of two panels. A control panel 
which contains the three buttons for adding, updating and removing curves and a chart panel. 
For implementing this chart, we created a new Visualization StepChart which inherits from the 
GWT Visualization type LineChart. LineCharts are usually used to create curves in charts, but 
they don’t support the creation of stepped curves, that means you can only set single points that 
are connected by a rounded line. The new class StepChart uses all functionalities of the class 
LineChart but adds a new function addStep(int x, int y) that creates instead of a single point, one 
point of the same height than the last point of the curve with the distance x and a second point on 
the same width than this new point but width the height y. In this way addStep creates angular 
plots instead of smooth curves. The advantage of inheriting from the GWT Visualization class is 
that our new class adopts the functions for the legend and tooltips. The legend automatically 
shows every curves which is added to the chart in the same color than the curve. This color is 
chosen randomly by the method getRGBColor() of the class Util.Color.  
The process of creating a curve is started by clicking the add or update button. After pushing one 
of the buttons the event GetQuery is fired. The tool waits until another tool caught the event and 
fires the answer event SetQuery which contains the query data. The SCM extracts the query and 
sends it to the backend, where it is used to collect the data from the database. In the current 
version of the tool the SEER database is used as data source but in the further development 
process other databases should be integrated. After the data is collected it will be translated into 
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a DTOSurvivalCurve Object that consists of a HashMap that contains the values. This DTO is 
sent back to the SCM, where it is used to calculate a new curve.   
 
 
Figure 21: Screenshot of the implemented Survival Curve Manager. 
 
4.2.4. Issues and Challenges 
The challenge in the implementation of the Survival Curve Manager was to get the query from 
the Visual Query Builder into the Survival Curve Manager. This problem of requesting data 
from other tools was solved by the help of events which are fired at the right moment. 
A second issue are the datasources. One of the goals of this tool is to compare the survival times 
for different therapies for a specific population. Unfortunately, until now the given databases 
don’t support patient focused therapy information. So that we’re only able to present curves for 
different patient attributes. 
 
 
4.3. Biological Pathway Visualizer 
In cancer research pathways are playing an increasingly important role in deciding treatment. 
The one-target, one-drug approach has not held up for the most types of cancer. Recent studies 
that deciphered the genomes of cancer cells have found a wide spectrum of different genetic 
mutations that can lead to the same cancer in different patients. Researchers hope that they can 
find the disrupted biological pathways caused by these mutations and use drugs that target the 
specific pathways for treatment. In this way researches could focus on their attention on just two 
or three biological pathways instead of dozens of mutations. 
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The Biological Pathway Visualizer (BPV) supports the physician with the ability to choose a 
biological pathway which is displayed with its genetic nodes and connections. This pathway can 
be analyzed with the patients’ data to get a new look on the pathway which shows the mutations 
and deregulations and its effects. If available the BPV provides additional information to the 
deregulated gene like drug or study information. 
 
4.3.1. Motivation / Clinical Scenario 
Understanding disease at the level of biological pathways has a great potential in providing input 
to clinicians and improve diagnosis and treatment of cancer in the future. Using patient data and 
pathway activity relevant to the disease can highlight the state of such pathways and enable the 
clinician to focus on the impact of any deregulations. Presented in a visualization it is possible to 
show complex pathways with their deregulations in a way the physician can easily grasp and 
recognize the targets where he can interfere.  
 
4.3.2. Specification 
 
 
Figure 22: Overview of the Biological Pathway Visualizer. 
 
The input of the Biological Pathway Visualizer consists of biological pathway layouts and 
reference information from a database and the patients’ molecular data. 
 
The interface is divided into two halves, the left shows the pathway in its original version, the 
right shows it after the analysis with the patients’ molecular data. Between these two halves a 
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button is placed that starts the analysis and a score is displayed that shows the resulting risk of 
this pathway. On top of the screen is a selection box where the pathways can be chosen. 
The different interactions of the pathway are drawn in different forms and colors. Activating 
interactions are shown in green lines with arrows at its end and inhibiting interactions are shown 
in red lines with an orthogonal line at the end. If a molecule is deactivated or not existent in the 
analyzed pathway the interaction and the element itself are drawn translucent. The effects of this 
deregulation are visualized in bigger lines for the interactions and in red colors for the 
molecules. An exception are deregulated molecules which contain additional information, these 
molecules are drawn in an orange color. Clicking the orange molecules opens a small text box 
which contains information to useful drugs or studies, as well as a link to the literature search. 
This link opens automatically the literature search with the information stored in the box as input 
parameters.  
 
The analyze button in the middle of the screen uses the selected pathway and the patients 
molecular data and sends them to the backend where they are analyzed. The result will then be 
presented on the right halve of the screen. 
Below this button a perturbation score is shown which presents the risk of this pathway in 
percent. 
 
Figure 23: Flow Chart of analyzing a pathway. 
 
 
4.3.3. Implementation 
The implementation of the Biological Pathway Visualizer differs to the implementation of the 
other tools since it’s mixing the typical elements of GWT, the GWT Visualization API and the 
InfoVis toolkit described in Chapter 3.2.4 InfoVis. The standard interface with the toolbar at the 
top and the controls in the middle are still implement by using GWT elements. The toolbar uses 
a selection box to choose the pathway and a button to load it. The main screen is divided into 
three parts where the middle section is used for the controls. It contains an additional selection 
box for the therapy option, a legend that describes the particular elements of the pathway and a 
button for the analysis of the pathway. This analysis is done by an additional module developed 
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by the Philips research group, which provides methods to compare original pathway data with 
the data of the patient. An additional component, which is located below the legend, is the gauge 
that shows the perturbation score of the current pathway analysis. This gauge is an element of 
the GWT Visualization API and is integrated within the GWT code directly. The pathways are 
implemented besides this middle section, the original pathway without any modifications on the 
left side and the analyzed pathway with the modified molecules on the right side. As mentioned 
above we used the InfoVis toolkit to create the pathways. Since there aren’t any interfaces or 
wrapper classes for the toolkit, we had to generate a new class Pathway which creates an iframe 
that hosts our visualization. We used an iframe because it offers the possibility to implement 
inside it completely independent and it is easy to integrate into GWT. After creating instances 
for the original and the modified pathway we can load the pathways with the function 
loadPathway(String frameName, String json) into the iframes. The parameter frameName is the 
unique identifier for the iframe and json is the data string that should be loaded. This method is a 
JavaScript Native Interface (JSNI) method that means it is declared native and contains 
JavaScript code in a specially formatted comment block. This special format is a directive to the 
Java-to-Javascript Compiler to accept any text between the comment statements as valid 
JavaScript code and inject it in the generated GWT files. In this way we can build a 
communication between the GWT code and the JavaScript files. The visualization itself is done 
in separated html and javaScript projects which are loaded into the frames. In this way the html 
file loads the InfoVis library and builds the container for the visualization which is loaded into a 
<div>- Element. The JavaScript file for the pathway is more complex it has a defined structure 
depending on the chosen visualization type. For the pathways we chose a SpaceTree as 
visualization type which has a root element and an unlimited number of children. It also provides 
options to modify the nodes and connections in colors and form. The json string from the 
loadPathway method is used as input and has a specific structure with node attributes and 
adjacencies, an example is shown in Figure 24. 
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[{ 
  'id': '1', 
  'name': 'MEK',  
  'data': ['$type': 'circle'], 
  'adjacencies': [{ 
                    'nodeFrom': '1',  
                    'nodeTo': '2',  
                    'data': { 
                              '$type': 'arrow',  
                              '$color': '#008B00' 
                            } 
                      }] 
} 
, 
{ 
   'id': '2',  
   'name': ‚PI3K‘,  
   'data': ['$type': 'circle'],  
   'adjacencies': [{ 
                     'nodeFrom': '2',  
                     'nodeTo': '3',  
                     'data':{ 
                               '$type': 'arrow',  
                               '$color': '#008B00' 
                             } 
                       }] 
}] 
Figure 24: Example JSON string for pathway input. 
 
Special attention was needed for the popup window which appears by clicking a highlighted 
molecule. The creation of the popup and the event which leads to the opening of the window was 
done by functions of the InfoVis toolkit. However, the integration of the Literature Search was 
more difficult because our GWT project has to react to an event which happened inside the 
iframe. To build this communication we created again a native method 
registerLiteratureSearchClickListener(String name) on GWT side which connects the method 
literatureSearch(String term) of the iframe with the method fireLiteratureSearchEvent(String 
term) of the class Pathway. Now, each time the „search literature“ button is clicked the event is 
forwarded to the method fireLiteratureSearchEvent which opens the Literature Search tool. 
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Figure 25: Screenshot of the implemented Biological Pathway Visualizer. 
 
 
4.3.4. Issues and Challenges 
The Biological Pathway Visualizer is the most complex tool of our collection. It handles a very 
new type of data and we’re trying to present it in a new way. 
So the first challenge that occurred was the integration of the already available pathway data into 
the tool. This data is mostly stored in the BioPax (Biological Pathway Exchange) format which 
is a RDF/OWL-based standard language that tries to standardize the creation of new pathways. 
Since the structures and interactions which are based on the pathways are very complex also the 
BioPax files are getting very big and complex. So it would take a lot of time only to extract the 
necessary information out of the files and to create an input stream for our tool. Since our focus 
is mainly lying on the visualization of data and not in pre-processing the available data we 
decided to use simplified example data for the first release. This example data is stored in a local 
database within two tables. One table for the molecular elements of the pathways and a second 
table that contains the interaction between these elements. In this way in later releases the 
BioPax data can be adapted and stored in the database to integrate pathways into the tool without 
changing the code. However, we also have developed a simple and extensible to use tab limited 
format for encoding pathway information that can be used for any other pathway. 
Another challenge was the integration of the InfoVis toolkit into the GWT project. Since there is 
no wrapper or interface class yet we had to find a different way of integration. With the help of 
iframes and JSNI we created a complete different structure as in the other tools that make a 
communication between the two different languages possible. The exact implementation is 
explained in Chapter 4.3.3 Implementation. 
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After we integrated InfoVis into GWT we were facing to the question of which type of graph we 
should use. We tried several possibilities from simple graphs over special graphs like weighted 
graphs to more complex trees. But the problem we had with all these types was the ordering of 
the elements. The graph orders the elements randomly so every time we created a new graph we 
got a new ordering what is unhandy because it is very complicated to compare two graphs even 
if they differ in one element. The tree has a similar problem, here you can’t remove a node that 
has a subnode since every element needs a parent. To solve these problems we decided to 
change our imagination of the pathway a little bit. Instead of removing an element completely 
from the visualization we decided to mark it as removed. This solution has the advantage that we 
can use a tree to draw the elements and as a second effect it is easier to see which elements differ 
from the original pathway because they are drawn in a translucent way. 
 
4.4. Geographical Trial Finder 
Clinical Trials are research studies in which patients and doctors work in an improvement of 
health and cancer care. Each study tries to answer a specific scientific question and tries to find 
better ways to prevent, diagnose or treat cancer. 
The Geographical Trial Finder helps the user to search and find the right trials in huge databases 
like ClinicalTrials.gov. The results will be presented in a common list as well as a geographical 
list that shows the locations of the study. Additionally, this search can be filtered by specifying 
the location, choosing a study type and so on. Markers on the map are containing the description 
and information to the according trials. 
4.4.1. Motivation / Clinical Scenario 
Very often the last chance for cancer patients with difficult or uncommon cancer types is the 
attendance in clinical trials. These trials are using new drugs and treatment methods to find out 
whether promising approach is safe and effective. But also in the treatment of more common 
cancer types it is important to improve the different steps that lead to a cured patient. So the 
most cancer patients decide to attend in a clinical trial. In both cases it is important to know 
where appropriate trials are located so that patient can decide which research facility looks the 
best for him and where he feels most comfortable. Today, the www.clinicaltrials.gov is the 
repository for all registered trials in the United States. However it is difficult to navigate and 
does not provide even preliminary filtering options that are available in consumer-focused 
websites. Our motivation is to overlay clinical trial data onto a geographical maps interface such 
as google maps that would allow patients and caregivers alike to be able to identify clinical trials 
that are applicable to the current patient, 
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4.4.2. Specification 
 
 
Figure 26: Overview of the Geographical Trial Finder. 
 
As input the Geographical Trial Finder requires a study database like ClinicalTrials.gov that 
contains values for the title, description and localization. Additionally pre-defined values as from 
the patient data can be loaded to make a pre-selection of the search values.    
The interface is divided into three parts. The search form, which is located on the top of the 
screen - the geographical map that takes the main part in the central of the screen and the search 
result panel which is located on the right of the screen. The search form and search result panel 
are collapsible that means they can be closed so that only a small bar remains. Then the map 
uses almost the complete screen what makes it easier to look around. 
The search form includes the elements that are needed to perform a study search. These are: 
• Search Term 
• Status (all / open / closed) 
• Results (all / with / without) 
• State 
• Country 
• Gender 
• Age Group 
• Phase 
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These values are filled out automatically if the pre-defined values are set. The search term is set 
by external tools and the patient according values gender and age group are set by the patient 
data that is stored in the system. 
The search result panel contains a paging list that takes a maximum of ten studies at the same 
time. The list shows the values  
• Study ID 
• Title 
• Facility 
• City 
• Zip 
• State 
• Country 
of every study, whereas the studies are grouped by their study ID. In this way each study with at 
least one location is shown in the list, but the study also can have unlimited other locations that 
are also listed. 
The geographical map contains controls for zooming in and out and moving around. Each study 
location that is found gets a marker on the map. These markers include information about the 
title of the associated study and a short description that is opened in form of a cloud by clicking 
the marker. For supporting the user, the result list and the map are connected. If a study in the 
list is clicked, the map will zoom to the associated marker. On the opposite if a marker is clicked 
the associated study in the list will be selected.  
The initial screen shows the search form with selected values if available and the geographical 
map. At this time the search result panel is closed. After initiating the search the search form 
closes automatically and the search result panel opens and shows the found studies. Then the 
locations of the results will be determined and positioned in form of markers on the map. In this 
way the map uses the most available space at any time. But of course the user can also control 
the state of the panels and open and close them as desired. The complete procedure of searching 
is shown in Figure 27. 
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Figure 27: Flow Chart of searching and locating trials. 
 
4.4.3. Implementation 
The interface of the Geographical Trial Finder (GTF) is divided into three parts as described in 
the specifications. The search form is the simplest component it’s a plain, collapsible panel that 
includes the different kinds of Text Fields, Selection Boxes and Checkboxes which represents 
the search parameters. During the initialization the patient data is loaded and the patient-specific 
fields such as gender and age group will be filled out automatically. The search result panel is a 
little bit more complex. It contains a pageable list that shows a maximum of ten trials on one 
page. These trials can be extended by clicking the „plus“ in front of every trial to show all the 
locations of the according trial, with the facility name, city, zip and country. The third part takes 
the geographical map. It is realized by integrating Google Maps. Google Maps isn’t part of the 
GWT but the official Google Maps API library for GWT provides a way to access the Google 
Maps API from a GWT project without having to write additional JavaScript code. After 
including the library we can instantiate an object of the class MapWidget which represents a 
single map with all features. These features cover zooming and moving the map as well as the 
creation of markers that is used to locate the trials on the map. Also these markers contain the 
title and description of the according trial which they show after clicking it.  
The localization of the trials follows three steps: 
In the first step the search is used to find the relevant trials. After submitting the search form, the 
GTF sends a request with the search parameters to the backend. The backend searches in the 
specified database for the trials, translates each of them into a DTOTrial object and put them into 
a list that is returned to the GTF. After getting the results of the search, the second step is 
following in which the trials are grouped by their ID and loaded into the search result list. In 
Step three the location attributes of each trial will be translated into geographic coordinates 
(latitude/ longitude) which can be pointed on the map. This translation is called geocoding and is 
also included in the Google Maps API. The geocoding service makes a call to an external server 
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where the sent data is used to query a huge database. In this database all the text based location 
data like cities, zip codes, streets, etc. are stored in different combinations with their according 
geographic coordinate. After the tool gets the coordinates it creates for every found point a new 
marker and sets its title and description text. This step is repeated every time the data in the list 
changes, what means every time the shown page is changed or a new search is started. 
Above the search result list an additional button is available that uses the trial descriptions to 
generate a new Interactive Word Cloud. 
 
Figure 28: Screenshot of the implemented Geographical Trial Finder. 
 
4.4.4. Issues and Challenges 
The first challenge in the implementation of the Geographical Trial Finder was to get the data 
from the data source into the tool. In this first version of the tool we used ClinicalTrials.gov as 
data source. This caused the problem that the data is located on an external server which is not 
accessible via JavaScript thus to the Same Origin Policy (SOP). SOP is a security concept that 
prevents access to methods and properties that aren’t in the same domain than the original page. 
So we implemented the search mechanism in the backend which has no restrictions for accessing 
external servers.  
The next problem was the format in which the locations are stored at ClinicalTrials.gov. They 
are saving only the written addresses of the locations, means street names, city names, zip codes, 
etc., but geographic map (Google Maps) provides only methods that generate markers for 
geographical coordinates. So we had to translate these written addresses to geographic 
coordinates before we can use them. This can be done by a service called geocoding. The 
Google Inc. offers such a service in connection with GWT so that we could use it directly in our 
code. Unfortunately the Google Geocoding API is subject to a query limit of 2.500 geolocation 
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requests per day and not closer defined limit of request in a short interval. We tried to avoid this 
limiting by using other services like the Yahoo PlaceFinder, Bing Maps, OpenStreetMaps, etc. 
but all of them have restrictions in querying the data or it wasn’t possible to use the service in a 
reasonable way. A different idea was to generate our own geocoding service. We took the 
necessary data for two states of the US from OpenPHI [24] and put them into a database. We 
used only the data of two USA states as a proof of concept for our prototype, but in theory this 
can be scaled up. Each data package consists of fields for the available addresses as well as the 
belonging geo coordinates of the state. Then we implemented a small interface that searched for 
the incoming addresses in the database and got the geo coordinates as result back. This approach 
was very promising but it needs a very huge storage and time to install which we didn’t want to 
spend at this moment, so we decided to use the Google Geocoding API and perhaps develop this 
method for a later use. 
 
 
4.5. Literature Search 
The Literature Search is a tool that supports clinicians with a simple but powerful way of text 
based searching. It provides a simple UI with a search field but also with a large amount of filter 
functionalities that makes the search more precise. The results are shown in a paging list that 
shows the attributes title, author, publication and publication date. Each entry also includes a 
short description text which is shown by expanding it and can be opened in a full information 
page. The complete tool is connected to the Interactive Word Cloud and can summarize the 
results with the use of it. 
4.5.1. Motivation / Clinical Scenario 
In a time where dozens of books and publications are published every day it’s almost impossible 
to read every new article or to remember every text you read. But it’s very important for 
clinicians to stay up to date. They have to know the newest developments in medicine when a 
patient is asking. For this reason a tool is necessary that supports clinicians with a simple and 
fast access to these large repositories. Such a tool can help finding clinical relevant publications 
for a current patient without searching in all the databases currently available.  
 
 
 
 
 
           Chapter Four: Development   
 
 
53 
4.5.2. Specification 
 
Figure 29: Overview of the Literature Search. 
 
The input of the Literature Search consists of one or more text based databases which contains at 
least the attributes title and description. Additionally pre-defined values from external tools can 
be used to automatically fill out the search term and the filters.  
 
The interface consists of a toolbar that contains the general controls, a filter bar and a pageable 
list for presenting the results. 
The toolbar includes a search field in which one or more words can be insert, a button that 
transfers the results to the Interactive Word Cloud and a button that opens and closes the filter 
bar.  
After opening the filter bar several options of filtering are available.  
• A search builder that provides the possibility to search for a word that only exists or 
especially not exists in a specific field.  
• A keyword list in which often occurring words can be excluded. This list will be created 
after the first search and can be used to specify a second search. 
• A filter for the publishing date in which the publishing date can be limited to a specific 
range. 
• A language filter that limits the searched texts by their language. 
The result list shows a maximum of 20 entries on one page, the controls that enable the browsing 
through the pages are located at the bottom of the list in a second toolbar. This toolbar also 
contains three buttons for printing, emailing or creating a pdf of the results. The entries are 
represented in the list with their 
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• Title 
• Author 
• Publication 
• Publication Date 
 
By clicking an entry it expands and shows a short description of its content. Making a double 
click on an entry opens a new panel that contains the full information about the entry including.  
 
A search can be started automatically if the tool is opened from an external tool or directly by 
clicking the search button in the toolbar. The search needs at least one word in the search field 
that it can be executed. The filtering can be configure before the first search or after every search 
to get a more exact result list. Helping to get an overview it’s possible to summarize the results 
in form of an Interactive Word Cloud. The possible procedure of searching is shown in Figure 
30. 
 
 
Figure 30: Flow Chart of searching for literature. 
 
4.5.3. Implementation 
The Literature Search tool is implemented in the three classes LiteratureSearchView, 
LiteratureSearchFilterBar and LiteratureSearchDetailWindow.  
The LiterSearchView is the main class of the tool, it contains the UI elements and the services 
that communicate with the backend. The UI is structured in four graphical components which 
are ordered in a vertical line. The first element is a toolbar in which the search field, a button for 
the creation of Word Clouds and a filter button are placed. Below this toolbar a second 
collapsible toolbar follows that contains the possible filter options for the literature search. It can 
be opened and closed by clicking the filter button in the first row. Since the standard toolbar of 
GWT doesn’t support the functionality of collapsing we created a new class 
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LiteratureSearchFilterBar which inherits from the class ToolBar and coded the functionality of 
collapsing on our own. The new filter bar currently consists of four filter types: 
• A Search Builder that is realized by two selection boxes that include the fields (All 
fields / Title/ …) and the condition (And / Not) and text field for the search term. The 
created items are stored in a list of HashMaps in which every HashMap includes the 
fields name, variable, operation and value.    
• A keyword list that shows the five most occurring words of the last search. Every time 
the result list changes, the service getKeywords(List<DTOLiterature>) is used to send 
the text to the backend and get a new list of keywords back. 
• A date filter that shows a selection of dates like the last 30 days / the last 60 days / etc. 
• A language filter that shows the common languages English/ French/ German/ Italian / 
Spanish with checkboxes so that none (same as all) or any number can be selected.  
Every time a search is started or the refresh button is clicked, a DTOFilter will be created that 
includes all parameters of the filter bar and will be sent along to the backend.  
The main element of the tool is the result list which shows the found literature in descending 
relevance. Every item shows the title, author, publication and publication date of the literature 
and every item is collapsible. That means by clicking the „plus“- button in front of an item 
extents that item and shows a summary of the according literature. Double clicking an item 
creates a new object of the class LiteratureSearchDetailWindow which represents a full 
information page of a literature item. It inherits from the class Window and in this way slides 
over the tool itself. The window shows again the title, authors and institution in which it was 
created as well as the full text if available or instead an abstract of the text. Furthermore it 
includes information about the journal or book in which it was published with the ISSN and 
publication date. 
The bottom component is the paging toolbar which includes elements to control the paging and 
also includes buttons to print, email or create a pdf of the literature.  
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Figure 31: Screenshot of the implemented Literature Search. 
 
4.5.4. Issues and Challenges 
The first problem that occurred in the process of implementing the Literature Search tool was the 
fact that there are only a few databases out there which can be used by external tools. Most 
medical databases are on commercial use and have their own search systems. The first database 
which provides external access is also one of the biggest medical literature databases, the 
PubMed database [7]. But also PubMed doesn’t support an open access to their databases, 
instead they offer different services which can be used to query the database. That means we 
didn’t have to code our own search algorithm but use the PubMed algorithms. On one hand this 
is a big advantage because the algorithms used by PubMed are very professional and complex 
but on the other hand we can not transfer this search to other databases.  
We implemented the tool as open as possible so that in the further development only search 
algorithms must be written for new databases but all other functions can be reused. 
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4.6. Interactive Word Cloud 
A Word Cloud is a visualization of word frequencies in a given text as a weighted list. The 
higher the occurrence of the word the higher the weight and the bigger the font in which the 
word is shown in the visualization. In this way words that are occurring very often in the text are 
bigger than others and catching the eye.  
The Interactive Word Cloud combines the features of a typical Word Cloud with two interactive 
options. One is to remove unimportant words, for example a date that occurs very often, and 
then recalculate the Word Cloud to get a new result in which now other words are shown bigger. 
The second option is to select one more words directly in the Word Cloud and start a new 
literature search that automatically uses these words in the search.      
 
4.6.1. Motivation / Clinical Scenario 
Time is a factor that is very rare in the work of clinicians. In this way the Interactive Word 
Cloud supports clinicians with a simple method of summarizing clinical terms related to a 
current search. This can be a search for literature, studies or any other text based search. 
 
4.6.2. Specification 
 
Figure 32: Overview of the Interactive Word Cloud. 
 
The Interactive Word Cloud accepts all kinds of text based data as input. The texts can come 
from literature, studies or whatever is included in the application.  
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The interface consists of three parts. A filter bar in which the applied algorithm, form and sorting 
order can be changed, the Word Cloud itself and a button bar that contains a button for 
refreshing or closing the Word Cloud or starting a new search with the selected words. 
 
The filter bar contains the following three possibilities with their options: 
• Algorithm 
⁃ Linear 
⁃ Logarithmic  
• Form (Currently only one form but should be extended in the future)  
⁃ Random  
• Sorting Order 
⁃ Alphabetical 
⁃ Descending Word Count 
The changes of these options take effect after using the refresh button.  
 
The Word Cloud allows two types of interaction. By clicking words with the left mouse button 
the words are getting selected an can be used to start a new search by clicking the search button. 
Clicking words with the right button marks them as removable and they won’t be included in the 
next calculation of the Word Cloud. 
A possible application of the Interactive Word Cloud is shown in Figure 33. 
 
 
Figure 33: Flow Chart of using the Word Cloud. 
 
4.6.3. Implementation 
The Interactive Word Cloud (IWC) is implemented in a single class WordCloud that inherits the 
also self coded class AbstractTextSummary. We decided to write a superclass for the IWC 
because we assume that more other text visualization types are following and in this way we can 
reuse some methods like the sorting of the keywords. Furthermore, we can define the structure 
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of the subclasses and make methods required which helps to create new tools and to maintain 
them.    
The IWC can be initialized in two ways, it can be created directly as an object of the class 
WordCloud what makes it to a simple LayoutContainer or as an instance of the class 
TextSummaryWindow. In this way it can be placed over any other tool or element and it gets a 
nice slide in and out effect. The IWC itself doesn’t change no matters in which way it is used. At 
any time it consists of a toolbar with design options at the top, a button bar for interaction at the 
bottom and the Word Cloud itself in the middle of the tool. 
There are three ways to modify the Word Cloud, switching the sort order between alphabetical 
and count based, changing the form (currently only a random form is implemented) or choosing 
a different algorithm. The algorithm is the heart of the Word Cloud it calculates the font sizes of 
the words by their word count. We implemented a linear algorithm which shows the size of the 
words in relation to their actual occurrence and a logarithmic algorithm that interpolates the 
counts of the words. The linear approach shows a good overview if the distribution of the counts 
is even, but if outliers exist they distort the result by highlighting these outliers and ignoring the 
smaller ones. In this way the differences in the word counts of the actual text are vanishingly 
small. The logarithmic algorithm balances this distribution by interpolating the word counts. 
This helps to get a distribution of font sizes covering the complete available range and inhibits 
the importance of outliers.   
The Word Clod itself will be created from a list of DTOKeywords which consists of the name 
and the count of the word. Each of these words creates an instance of the class WordCloudText 
which inherits from the class Text. This special class has additional features like hover, selection 
and strikethrough styles. The selected and strikethrough elements are additionally stored in 
separate lists, so that the access is easier and faster. After the list of WordCloudText objects is 
created the words are placed in a panel according to the algorithm, form and sort options. 
On the bottom of the screen is a small button bar which contains the components „Refresh“, 
„Close“, and „Search Literature“. The refresh button uses the information of the option bar 
(algorithm, form, sort) and the strikethrough list to generate a new cloud. In this cloud the words 
of the strikethrough list are removed and the remaining words are presented in form of the 
selected options.  
The close button usually just close the container but is overwritten by a slide out animation if the 
TextSummaryWindow is used. 
The third button is the search for literature button which connects the Word Cloud directly to the 
literature search. It fires the LiteratureSearchLoad event with the words of the selection list as 
input that opens the literature search and automatically starts a search with the selected words.   
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Figure 34: Screenshot of the implemented Interactive Word Cloud 
 
4.6.4. Issues and Challenges 
Word Clouds have two general challenges. Find the right algorithm that distributes the counts 
most evenly and find a form that shows the words in the clearest way.  
We decided to implement two algorithms a linear and a logarithmic one to give the user the 
possibility to decide which one he prefers. The both algorithms are described in more detail in 
Chapter 4.6.3 Implementation. 
The form is the second important options in implementing a Word Cloud. It is possible to place 
the words in a line, in a spiral or totally random. For the beginning we implemented a simple line 
design and kept other forms for future versions. 
 
4.7. Tool Interaction 
Building intelligent tools is one big step in the creation of a helpful web platform. Each of these 
tools helps to answer a specific medical question. But it is possible to even improve that 
usability by building connections between the tools. In this way, it is possible to use the output 
of one tool as input for another or simply switch from one to another. This creates a more 
intuitive flow of the application and reduces the unnecessary actions by the user. There are 
different ways of interaction, one way would be to request data or queries from another tool like 
the Visual Query Builder to modify the own data. A second possibility is the direct loading of 
one tool within another tool, as example starting a literature search by selecting a word in the 
Interactive Word Cloud. Figure 35. shows an overview in which way the tools can interact with 
each other and what types of data they are exchanging. 
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Figure 35: Interaction between the tools. 
 
A challenge of this functionality is the changeability of the tools the requirements demand. It 
makes it impossible to implement static connections, since at their initialization none of the tools 
knows about the existence of the others. To solve this problem we used another functionality of 
the GWT that uses events and event handlers to communicate and exchange data between 
objects. All available event types are declared in the web application and can be called by any 
tool. The event handlers are declared within the specific tools, which has use for. If an event is 
triggered all tools that have a handler for this event will automatically execute their method for 
this event. If there is no handler in the complete web application for an event type nothing 
happens.   
To make this process more understandable we look on the communication between Visual 
Query Builder and Survival Curve Manager as an example. Starting point is that the user wants 
to create a new curve in the Survival Curve Manager. To do this he selects the different values in 
the Visual Query Builder and uses the „New curve“ button within the Survival Cure Manager. 
Now the SCM triggers the getQuery event, which is sent to the main application controller that 
shares the event to each available tool. In this case only the VQB has a handler for the getQuery 
event. It executes the handler specific method, which creates a new query of the selected values. 
After the query is created the VQB triggers a new event sendQuery with the new query as 
content. Again all tools would have the possibility to handle this event, but since this query only 
sends data and doesn’t load a tool in the foreground, it has only consequences for the visible 
tools. In our case the SCM that accepts the incoming event and uses the included query to create 
a new curve. 
In a special case in which we had no handler for the getQuery event, the SCM would wait for the 
response until a defined time out and then shows the standard curve. 
These events can also be used to load a tool into the foreground and give him a starting value. 
The literature search can be activated from each other tool by using the loadLiteratureSearch 
event. If this event includes a search parameter it starts automatically a literature search and 
shows the results. All currently available events are listed in Table 3.  
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Event Type Description 
Init Initial Event for loading the Application. 
EpiLoad Event for loading the epidemiological tools. 
PieChartLoad Event for loading the Visual Query Builder. 
SurvivalCurveLoad Event for loading the Survival Curve Manager. 
GetQuery Event that requests the query from the Visual Query Builder. 
SetQuery Event that returns the created query to the active tool. 
GeoMapLoad Event for loading the Geographical Trial Finder. 
LiteratureSearchLoad Event for loading the Literature Search. 
LiteratureSearchFilter Event that requests the filter, which is used for the Literature 
Search. 
PathwayLoad Event for loading the Biological Pathway Visualizer. 
Table 3: Available event types of the web application. 
4.8. Backend 
The backend is the control center of the web application. It is located on a web server and 
contains interfaces for accessing the different data sources, functions for pre-processing the 
incoming data and a controller that manages the incoming and outgoing events of the 
visualization tools. But why do we need to encapsulate the data processing out of the tools? The 
goal of each of our tools is only the visualization of data and not the processing of data. In this 
way the tools remain compact and can be loaded on the client side in a very short time. All the 
data processing and calculations are done on the server side and the results are sent to the client 
which also reduces the time the tools need to show the data. It gives also possibility to visual 
every data from every source if it is in the right input format. Another reason is the flexibility 
this design is giving us. Every function must only be implemented once and can be used in 
multiple tools. For example, we can use a search algorithm for the literature and also the same 
algorithm for the search of studies. Furthermore we can remove or add tools without affecting 
others. 
In the decision of which technology is best for the backend, we decided to use Java Servlets. 
Since we already wrote the client side in GWT specific Java classes it is practical to use the 
same technology for the server classes what makes the code more legible and understandable. 
Moreover, the GWT supports the use of Java Servlets by providing a special communication 
framework, called GWT Remote Procedure Call framework (RPC). The RPC makes it easy for 
the client and server components to exchange Java objects over HTTP by using services on 
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server side and an automatically generated proxy on client side. Another advantage of the RPC is 
the ability of asynchronous calls. That means the client can retrieve data from the server in the 
background without interfering with the display or the tool.  
The exchange of data between client and server is done by DataTransferObjects. These objects 
are simple serializable classes that only behavior is to store and retrieve its own data. They 
provide an easy way to collect the data in a single class that can be sent by services from the 
server to the client. All that is needed on client side are fill lists, selection boxes and other GWT 
components. Each object has at least one empty constructor and can be extended by an unlimited 
number of additional constructors. For every attribute in the object a getter and setter method is 
needed which change the value of the attribute.
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Chapter Five: Evaluation of the results 
The creation of visualization tools for presenting medical data was the main part of this thesis. 
However, we also wanted to evaluate these results and determine what we did good and what 
can be further improved. We did this in two steps: first we developed two additional tools that 
use the available functions and data of the backend but visualize them in a totally new way; and 
in the second step, we presented our web application to the three physicians we talked in the 
preparation phase before and asked them for their feedback.  
 
5.1. Extensibility of the Application 
One of the goals of the web application is to have a low redundancy of the developed functions. 
That means calculations and algorithms that are used by more than one tool are still written only 
once. A low redundancy also provides the application with a simple changeability and 
extensibility of new tools because only the presentation must be developed but the backend can 
be reused. For evaluating this we present two new tools in this chapter.  
The first tool is a Survival Bar Chart Manager and is similar to the Survival Curve Manager. It 
uses the same input data as the SCM that means a statistical database and the output of the Query 
Builder but presents this data in a different way. It shows the amount of patients who „died on 
cancer“, died on other reason“, „left study alive“ or are „alive“ after 1 year, 3 years and 5 years 
in form of bar charts. In this type of visualization it is possible to see the progress of the cancer 
as well as the censored data, broken down by their type. Like in the SCM, the Survival Bar Chart 
Manager contains a control panel in which new charts can be created or already existing once 
can be modified or deleted. Figure 36 shows a screenshot of the Survival Bar Chart Manager 
with two different cancer groups. 
 
 
Figure 36: Screenshot of the implemented Survival Bar Chart Manager. 
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The second tool is a text summarizing tool like the Interactive Word Cloud. Also in this tool the 
input is the same, it uses the same keyword function than for the Word Cloud to calculate the 
keyword counts. But instead of visualizing them in a cloud the tool generates a list of the 
occurring words and presents their counts in form of vertical bars. The higher the bar, the bigger 
the count of the word. Like in the IWC the list can be ordered alphabetically or numerically. 
Figure 37 shows a screenshot of the Keyword Count tool with the keywords for the search „Neo 
Adjuvant Herceptin“ ordered by their count.   
 
 
 
Figure 37: Screenshot of the implemented Keyword Count tool. 
 
Both tools are using the existent functions and data types. In this way it was possible to create 
each of these tools in just a few hours. The development shows that now where the most 
functions are existing in the backend the implementation of new visualization types needs only 
few time but can show totally new sights of the data.  
 
5.2. Interviews 
As mentioned in chapter 2.2 cooperation with the end-user is unavoidable. In a second interview 
we want to present our finished web application to the three physicians we interviewed before to 
get their opinion whether we implemented the tools as they imagined or not. For the presentation 
a prepared system with a demonstration dataset was built, which enabled consistent basic 
conditions. The presentation followed the storyline of a hypothetical patient which we used to 
present every tool and showed in which way it could help the physician and the patient. After 
each tool we discussed the advantages and disadvantages of the particular tool. The following 
paragraphs are summaries of the physician‘s feedback. Transcripts of the complete interviews 
are in Appendix C.  
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Visual Query Builder with Survival Curve Manager 
• Interesting interface and very intuitive. 
• Great benefit in presenting the patient advantages of different therapy options. 
• Not necessary for general decision finding but helps to validate the personal knowledge. 
• Maybe an option for very uncommon cases. 
• Very helpful for physicians or family doctors not intimately familiar with this data. 
Biological Pathway Visualizer 
• Very future oriented. 
• Currently, not enough information are available to make valid decisions. And the 
information that are available information aren‘t evaluated. 
• Not usable now but could be very important in the next five to ten years.  
• If pathways can be used for treating patients a tool like this will be absolutely necessary 
because nobody can remember all the available pathways. 
• Useful as eLearning tool for students or younger physicians. 
Literature Search 
• Nice and clear look.  
• Very intuitive. 
• More filtering options needed. Optimal solution would be different filters for different 
medical fields. 
• Not really applicable to clinical practice but very nice for scientific research.  
• Useful for very special cases. 
Summarizing tools 
• Nice idea and interesting interaction. 
• Not sure about the benefit of such a tool. 
• Wouldn’t be used in clinical practice but maybe to get an overview about a topic. 
Geographical Trial Finder 
• Nice components and look. 
• Very high usability. 
• Less relevant in Germany because of the smaller range. 
• Nice for patients who wants to know where a study is offered. 
• Results wouldn’t be of interest in such a tool because physicians have other sources. 
General impressions 
• Such tools would definitely be used. 
• Not only for physicians but also for patients and family doctors. 
• Should be available for everyone but with protected areas for medical personal. 
•  Nice looking application, especially the graphs that could help testing different medical 
scenarios.
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Chapter Six: Discussion 
The literature survey discussed in the beginning of the project provided us with four different 
data types, which could have great benefit from visualization. We used these data types to built 
six tools (chapter 4) that use different data to translate date into visual output. In these tools we 
implemented the newest types of interactive elements like animated charts that change their state 
dynamically depending on the incoming data. We built the tools to be intuitive for the clinician 
and provided automatization of the internal processes to a great degree. That means each tool 
uses the data of the current patient to automatically generate the output needed by the physician. 
This way, the physician can focus on decisions with all relevant information at hand. 
Furthermore, the tools aren’t isolated programs that show only their specified output. Most of 
the tools provide special functions and output that can be used by other tools, so that an 
interaction between the tools is possible. For example, the Visual Query Builder doesn’t only 
present statistical information, but also uses its graphs to create a query that can be used by other 
tools like the Survival Curve Manager. Knowing from the interviews that the needs for the tools 
depend on the medical field and the personal wishes of the physician, the tools are designed to 
be interchangeable. That means it is possible to integrate only the tools that are necessary for the 
work of the individual physician and hide those that are not needed without interrupting the 
interaction between the tools. For realizing this, the complete data processing and data 
formatting is encapsulated into the backend and only the presentational part is done in the 
particular tool. In addition, the communication cannot be done directly by method calling 
because the tools are unaware of the existence of the others. Instead we implemented an event 
driven communication system in which requests are broadcasted and every tool that has a 
handler for the event response to the request. In this way every tool constellation is possible. 
After the development of the application we evaluated our results by testing the extensibility of 
the tools (chapter 5.1) and presenting them to the group of physicians we interviewed earlier 
(chapter 5.2). We first implemented two new tools by using the available data and functions but 
visualize them in a new way. This demonstrates the ease of extending the application with new 
tools since the necessary structures are available and only new ways of presenting them needed 
to be developed. Only one day of development was needed for each new tool. It is important to 
note that in this case we used only data sources that were already integrated into the tool. 
Switching to new data sources will likely require additional time for new tool implementation, 
but even in this case, given the implemented functionalities can be reused. For additional data 
sources, only the mapping of the new attribute names and values need to be adapted. 
The underlying challenge for our medical decision support tools is the need of complete and 
valid datasets. If we take for example the Survival Curve Manager (chapter 4.2) the most desired 
feature of the physicians was the ability to compare different therapies and be able to show the 
different benefits to their patients. But even the SEER database doesn’t provide the possibility of 
connecting patients with their therapies in their public datasets. Our approach shows the 
potential utility in treating future patients if the data on past patients and their performance was 
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available to clinicians in an intuitive and straight forward way. Identification of a clinical partner 
who has access to such kinds of data would unload the full potential for this tool. But the 
problem of providing the application with the right data wasn’t the focus of this thesis. We 
aimed to create visualizations that can handle the available datasets and present them in a more 
informative way.  
In the final interviews with the physicians we presented the complete application and showed 
them all functions and opportunities of this new type of technology. The physicians were very 
open to the idea of a decision support tool included in their complete workflow. But their idea of 
the utility of the tools differed slightly. The clinicians also foresee a use in helping the patient to 
understand the process by which therapy decisions are made. The interviews showed us that the 
tools went in the right direction and would find a place in the workflow of the physicians, but 
there are still challenges that should be addressed in future work. Regarding epidemiological 
data for example, there is a need for connections between the patient and his/her therapy. This 
would improve the statistical tools because it would be possible to show the different effects of 
the therapies and it would be possible to show the absolute benefit of a therapy within a 
specified patient group. 
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Chapter Seven: Conclusion 
Data overload in medicine is a problem that’s getting more and more important over the last 
decades. In the coming years the amounts of data will be increasing rapidly with the use of new 
data types like high-resolution sequencing. In this thesis we used a new approach of visualizing 
data to solve the problem of data overload. The tools that were developed in this thesis show the 
potential of this idea. Simple but intuitive interfaces were created to present large datasets in 
form of compact and easily understandable graphs. We also demonstrated the benefits of 
interactivity between different tool types by making their use even more intuitive and provide 
streamlined instruction for the user. During the evaluation we also demonstrated how easy it is to 
create new tools and to extent the whole application by using the available functions. From the 
feedback by the physicians to which we presented our results, we conclude that this type of 
presenting data has high potential and physicians would benefit from a decision support tool that 
provides them with effective visualization and interaction tools.    
 
7.1. Future Work 
In this thesis we developed first prototypes of tools that implement our ideas of presenting data 
in a new and helpful way in a clinical setting. During this development and also with input from 
a group of physicians we collected additional ideas for improvement and additional tools and 
functionalities. One example of this is extending the literature search tool by using a Search 
Result Clustering Engine like „carrot2“[25] that automatically organize collections of documents 
into thematic categories. In another example, additional graphical data representation modalities 
such as glyph based medical visualizations can be used. These are explored by T. Ropinski [26]. 
Finally, additional data sources can potentially be used. For example, the physicians suggested 
integrating clinical guidelines in our tools.  
These tools can be provided to clinicians as a stand-alone application, but likely they will be 
used as components in a broader clinical decision support application. One possibility is 
integration of the tools into the PAPAyA platform [27] developed by Philips. This platform 
already integrates clinical tools around multiple molecular modalities, standard clinical 
parameters and contexts defined by clinical experts. Thus it’s flexible architecture it’s very easy 
to integrate new tools like the application created in this thesis.  
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Appendix B: First Interviews 
Interview Dr. Jörg Heil - 04.08.10 
 
Interviewer: You’re assistant physician at the Women Clinic of the University Hospital of 
Heidelberg? 
Heil: Yes, exactly. 
Interviewer: And in which medical field are you working? 
Heil: I’m working in the fields of mamma carcinoma, diagnostic, surgery and system 
therapy (Chemotherapy). 
Interviewer: What kind of data are you using in your daily workflow? 
Heil: We’re using general data like patient data, means age, medical conditions in 
general, medical history. Typical prognostic and prediction marker. 
In this field there are huge amounts of data or marker or measurements whose 
significance is sometimes more or less unclear. The complete gene expression 
profiling and everything else in this field is only more or less evaluated. And the 
better the evaluation is, the higher is the likelihood that it is used in routine ther-
apies.    
Interviewer: Do you already have tools or programs that use these data types?  
Heil: The only tool we’re using in this context is Adjuvant! Online. But very infre-
quent. You can use it if you have very enlightened patients for the question - 
chemotherapy yes or no. No other tools. 
Interviewer: These tools we’re planing to develop should work as decision support systems. 
In this context one idea is to show survival curves of our patient in comparison 
with a bigger population. Would a tool like this be of interest for you? 
Heil: What would you compare exactly? Therapies? 
Interviewer: We’re using the SEER database at the moment that includes parameters like per-
sonal attributes age, gender and also cancer specific attributes like tumor size or 
tumor marker. Unfortunately there are no therapies stored. But the purpose of 
the tool would also be to compare different therapies.   
Heil: But then it’s pretty similar to Adjuvant! Online. The only difference is that they 
don’t show Kaplan Meier Curves but just the absolute benefits in comparison.  
Interviewer: That’s right. The idea is similar but we want to integrate more possibilities, not 
only benefits.  
Heil: What do you mean with more possibilities? 
Interviewer: We would implement different views of the data, in form of curves or other vis-
ualizations but we would also connect the tools among each other. As an exam-
ple we could connect this tool with a literature search or a search for studies.  
Heil: That would be great. So that you could immediately verify the evidence of these 
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results. I guess that’s a good idea. Finally the question we’re interested in is 
what is the initial risk of a patient, means we have diagnosis with stage and a 
type of tumor and a specific situation, age, etc. And what happens if we do noth-
ing, what happens if we operate, what happens if we use radiotherapy or chemo-
therapy or something else. That’s definitely the interesting thing and not only for 
the physician but to show the differences in talks with patients. I’m not sure 
what other software is available, but that’s definitely an import field. That helps 
to make therapy decisions more transparent. And that’s what everyone want.   
Interviewer: Can you imagine any other data type that you’re using and that could be visual-
ized in any way? 
Heil: In the end, I guess, the relevant criteria are survival, disease free survival, local 
recurrence free survival and metastases free survival. And the relevant data for 
this are the validated prognosis and prediction marker. And I’m sure there will 
be always new types of this markers. Currently the best validated data is still the 
histological data but sure, in the close future we will have others like gene ex-
pression analyzes and whatever.  
There is really much research in this field but until something is validated so that 
you can make robust statements, still needs much more time. 
 Switching to Scenario 1. (Appendix A: Scenario 1) 
Giving general information about the interface and the overview page.  
Then switching to the population based graph tool.  
Interviewer: What do you notice if you’re looking at this tool? 
Heil: Definitely the therapy dependency. That’s the essential thing. If I can see that 
therapy A doesn’t change anything on the expected survival time, I don’t need to 
do it.  
Interviewer: In Scenario 1 Slide 9 you can see the way thought of visualizing this data. The 
idea was to show the different therapies to one of the curves in new charts that 
visualize the success of this therapy. In this example you can see that radiation 
has only a 38% of success but hormone therapy has a 80% of success. 
Heil: Okay. Yes that looks pretty good. 
 Switching to Scenario 2. 
Explaining the literature search. 
Heil: Looks like a classical search tool 
Interviewer: Right. But the advantage is the connection to the other tools. It’s possible to start 
a search from one of the other tools and our search tool automatically generates 
a search from the category you’re coming from and the word you started the 
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search. But of course you can also modify the search parameters. We also planed 
to extent this tool with summaries. One possibility would be to present the found 
words in a Word Cloud that displays each word in a different size depending on 
the relevance in the text.  
What do you think of that? 
Heil: I’m not sure about that because I’m not really familiar with the functionality of 
such Word Clouds. I have no idea how good they are. But finally it’s a tool to 
show the relevance and to make a relevance selection. And for this it’s good. 
Interviewer: From this point we could also jump directly to the clinical trials search and start 
an automatic search. 
 Explaining the study search. 
Heil: If I understand that correctly you’re target group were physicians so far. If you 
change, extent or adapt that target group to patients than this tool would be rele-
vant in particular. Because physicians have the character that - the studies I do 
on my own will be delivered and less others. And if I send my patient to another 
than to one of my friends.  That’s why I think it’s not that necessary for physi-
cians. But for patients who can search on their own for studies their interested in 
it would be absolutely brilliant.   
Interviewer: Maybe you’re right that the use is bigger for the patient. We should think about 
that. But you agree that it’s an approach of interest? 
Heil: Yes absolutely. 
Interviewer: Other ideas in presenting this data? 
Heil: No actually not. Sounds good for me. 
 Switching to Scenario 3. 
Explaining the pathway visualization tool. 
Heil: I’m sure that’s a very interesting approach but there are absolutely no data. As 
background information, our current procedure by advising therapies isn’t to 
say, „ok we have this complex molecular biological mechanism and we have 
this drug that intervene there.“ That’s not the way we’re working. Instead we 
take drug A, doesn’t matter how it’s working, and give it to patient XY and look 
after 10 years if this patient lived longer than the patient without the drug. It 
doesn’t matter why the patient lived longer. If they lived longer the next patients 
get this drug as standard. Shown absolutely simple and schematically. Maybe 
this approach in Scenario 3 is of interested for the people in the pharmaceutical 
industry who are developing but not for patient care. 
Interviewer: This tool is definitely more future-oriented but we can see big potential in this 
type of data. And we think that pathways are a good way to visualize this data. 
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Heil: Yes of course. That’s a huge are of development but currently it has absolutely 
no effect of the patient care.  
Interviewer: That’s the reason why we’re talking of hypothetical data. We’re aware of the 
fact that we still don’t have all the requirements for this type of tool. But we as-
sume that this will change in the next years. 
Heil: Okay but we’re talking of decades not of years. But it’s an exciting idea. 
Possibly you’re right and it’s the future. I can imagine that. Trastuzumab was the 
beginning of a multidirectional therapy and that’s more or less the same this 
pathway model will do. I’m sure the future is to figure out the exact genetic 
problem and find an antibody that works. But after Trastuzumab there was noth-
ing for a long time.  There are many developments in this field but until these 
„products“ are used in clinical routine procedures and especially in bigger 
amounts, I think we’re talking about decades. But an exciting idea, definitely.   
Interviewer: Finally I would like to ask you what you think of these tools and ideas in gen-
eral. Useful approach or wouldn’t you use it? 
Heil: I think it depends on the support the tool can really provide at the end. If it’s re-
ally helping in making therapy decisions transparent in a very detailed, nearly 
individual clinical situations then I’m sure it would be a sensation. That would 
be a further development and individualization of Adjuvant! Online. I’m sure 
that would be great and would be used in a wide field. But it depends on having 
a tool that can fast and visualized reflect an individual situation and helps in 
making considerations between no therapy and different therapies.  
Certainly, that’s a field that is very complex but that’s the reason why such a 
tool would be so helpful.  
Interviewer: Other comments? 
Heil: The only thing is that I’m really surprised that you do that as a master thesis. 
You could spend much more time in this research because it’s really a very im-
portant topic. 
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Interview Dr. Clemens Stockklausner - 06.08.10 
 
Interviewer:  First a few questions to your person.  
Where are you working? 
Stockklaus-
ner: 
Currently I’m working in the pediatric clinic.  
Interviewer: And what is your medical field? 
Stockklaus-
ner: 
Children Oncology. 
Interviewer:  What type of data are you using in you daily workflow? 
Stockklaus-
ner: 
 
We’re using data like leukemias. Similar to the risk factors you mentioned in 
your description. We also have different risk groups for standard risk, intermedi-
ate risk and high risk and these groups are depending on genetic factors, the re-
sponse, that means a defined area of success must be reached on a specific day 
of therapy. In other words, on day 8 the number of malicious cells in the blood 
count should be below a specific number, on day 15 the medulla should be more 
or less free from leukemia. And of course there are more genetic markers we are 
looking for. We have also PCR results that can detect minimal residual diseases 
in the process. Out of these factors we calculate a risk profile.   
Interviewer: And in which way is this data used at the moment? 
Stockklaus-
ner: 
 
At the moment we have this data in our mind and process them step by step. For 
example when we get a result we can look if the risk level changes or not. That’s 
the way we are using it currently. This data aren’t that complex but the amount 
is big. 
Interviewer: Would you prefer to get this data in a visual way to make it easier to work with 
it? Maybe you have a concrete idea? 
Stockklaus-
ner: 
 
Maybe in form of an interview, in which the system asks you questions like,  
„Is it a leukemia?“ -> „Yes“ 
„How is the response? Is it an A or B?“ -> „B“ 
In some kind of a tree structure in which you’re going from branch to branch. 
And at the end you get the right indication for the right therapy. 
You could also also for the response on day 8. Either good or bad, if you choose 
bad you’re automatically in the high risk branch. And from there you have new 
decisions. And there it’s going to get pretty complex and tough to remember. It 
would be very nice for young physicians to go step by step through such a visu-
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alization and could find the right therapy at the end. 
Interviewer: Do you have any other idea of data types? 
Stockklaus-
ner: 
No, not at the moment. 
 Switching to Scenario 1. (Appendix A: Scenario 1) 
Giving general information about the interface and the overview page.  
Then switching to the population based graph tool.  
Stockklaus-
ner: 
I find this idea a little bit critical, because to calculate an exact prognosis is 
tough. Of course you can do that but I wouldn’t push it to the foreground. You 
should know that neither we nor the patient always want to know the exactly 
prognosis. An integration into standard, intermediate or high risk is enough in 
principle for us. We wouldn’t calculate statistical survival times for patients.    
Interviewer: That means you can’t see any advantages in getting statistical information about 
the possible survival times of your patient? 
Stockklaus-
ner: 
Of course sometimes it’s interesting for us and then we find this information but 
actually it’s not necessary for us.  
Interviewer: The idea behind this tool was not only to present survival times for the patient, 
but to compare our patient with patients of the population with similar parame-
ters that differ for example in the therapy. So you could see what statistically 
happen if you choose therapy A or B. 
Stockklaus-
ner: 
But the tumor therapy for children is a little bit more special, because there are 
standardized therapy methods that must be used. We’re not allowed to look into 
a database what other people have already tried. That is more or less prohibited 
and is only allowed if there is a recurrence and we don’t have an established 
therapy protocol for this. But that’s a very special case. For this curiosities we’re 
also doing literature surveys but I think that’s a little bit too special. 
Interviewer: That’s depending on the available data but actually it’s a good example where 
you could use our tool. 
And you said you’re doing literature survey for that special cases? That’s perfect 
because as you can see in the other scenario we also provide a literature search 
tool which can help you searching for literature more automated.  
Stockklaus-
ner: 
I guess it’s very difficult to develop a program that automatically searches for 
the right literature. But it would be absolutely useful. 
Interviewer: Of course the tool can’t automatically know what you’re looking for but it can 
use keywords from the topic where you are coming from to support you and it 
can provide you with helpful filters. Making the effort as low as possible. 
Stockklaus- OK yes that seems possible. Or often you just want to find the reference to an 
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ner: established therapy method. For that you could create a link between the therapy 
method an the literature. Then you don’t need to search for the literature or you 
could provide the text directly.    
Interviewer: Additionally to the search we were thinking about a tool that summarizes texts. 
In the example in Scenario 2 Slide 8 you can see a so called „Word Cloud“. 
That’s a tool that visualizes the found expressions with their relevance. Words 
that occur more often are displayed in bigger letters. 
Can you see the advantages of such a tool?  
Stockklaus-
ner: 
No, not really. I can imagine a father that is searching with google for tumor 
information but I think an expert should have the basic knowledge that he 
doesn’t need such a summarizing. Usually he’s looking more specifically for 
articles. 
This tool with the map, where you’re searching for studies is also more interest-
ing for adults. There is not really a need for. In the field of child therapy it’s dif-
ferent. 
Interviewer: What does that mean exactly? You don’t use studies or you’re using them in a 
different way. 
Stockklaus-
ner: 
We’re using only a specific type of studies but this studies are multicenter stud-
ies, means different centers are offering the same study. And I guess it is very 
difficult to create an overview about this centers. Only the particular center can 
give you the information who is offering the study.  
Interviewer: Isn’t there a central register that stores the available studies? In America there is 
the webpage clinicalTrials.gov that stores the studies in the USA and also inter-
national studies. And they’re saving all information about this studies including 
descriptions, results and also the location.   
Stockklaus-
ner: 
No, unfortunately not. Or, definitely not for children. I’m not sure how it is for 
adults, but for children I’m pretty sure there isn’t anything like this.  
Interviewer: The next tool we have is more future-oriented and also the data we use are more 
hypothetic. It uses molecular data to display genetic pathways. It should help to 
visualize the effects of deregulated genes in a pathway. Of course with looking 
on our patients data. 
Are you already using genetic data or would you use it? 
Stockklaus-
ner: 
Yes we’re already using it but I would give you the contact information of one 
of my colleagues who knows more about it. 
Interviewer: May I ask you anyway in which range you’re using this data? 
Stockklaus-
ner: 
I’m not using the data by myself, but they are used. 
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Interviewer: Why don’t you use them? Because it’s not your topic oder because you can’t see 
the use of it. 
Stockklaus-
ner: 
That’s not so simple. We know that specific tumors have a molecular genetic 
risk profile. But the fact that a patient has a molecular genetic risk profile dis-
sents a little bit the german gene diagnostic law. This law says that I’m not al-
lowed to completely screen a patient for genetic defects, because that could be 
insurance relevant as an example. Instead of this I have to look on specific genes 
and for this the patient has to sign for every gene. All that means that the gene 
diagnostic law prevents the human to be classified completely as a risk profile.    
Interviewer: But if you familiar with Oncotype DX, they’re using only the 16 potential risk 
genes. Of course only for breast cancer but I think it’s not necessary to check 
every gene.  
Stockklaus-
ner: 
Of course, if we have a patient with a tumor disease and we recognize that the 
family is often affected by tumors, we’re looking for this family risk genes and 
advise the family adequate. 
Interviewer: But that means you’re not reluctant to the ideas of gene profiles? 
Stockklaus-
ner: 
No not reluctant. But I think that’s dreams of the future because there isn’t and 
I’m not allowed to do a global screening for risk factors. Furthermore this 
screenings are still very expensive and not really relevant. We don’t do more 
tests because we have this or that profile. 
Interviewer: The last question I have is more general, now where you have heard our ideas. 
Can you see the benefits of such tools and would you use them?  
Stockklaus-
ner: 
Of course I would you use them. But it shouldn’t be too unprofessional. It 
should be a specialized application and the purpose should be defined exactly. 
Then I could well imagine and think it’s really good idea. But you couldn’t de-
velop one for all fields. Instead you would need an own tool for any medical 
field or tumor group and have to think very exactly about the needs of the par-
ticular. 
 
 
  
           Appendices   
 
 
87 
 
Interview Dr. Florian Schütz - 10.08.10 
 
Interviewer: You’re senior physician at the Women Clinic of the University Hospital Heidel-
berg? 
Schütz: Yes that’s correct. 
Interviewer: And in which medical field are you working? 
Schütz: At the moment I’m the vice-chairman of the hospital of Salem. 
In this position I’m reasonable for the whole field of the gynecology and perina-
tology. But the medical field I’m usually working in is the gynecological oncol-
ogy and perinatal medicine.  
I’m also a member of the AGO and working there in the development of guide-
lines in the breast commission of the german cancer society for breast cancer. 
Interviewer: What types of data are using in the field of oncology? 
Schütz: I think the main data we’re using are study data, patient data, clinical data and 
histological data. 
Interviewer: What is with other data like genetic data?   
Schütz: Genetic data only in special cases. If we have genetic prepositions for example 
there is DSG 1 and 2. But that’s very rare, only 5% of all mamma carcinoma 
patients.  
Interviewer: That means genetic data aren’t really useful for you at the moment? 
Schütz: More in research. In this field we’re using it quite a lot. 
Interviewer: Do you already have any tools or applications that work with this data types? 
Schütz: My brain. 
Interviewer: So you don’t have any „computer“ program for that? 
Schütz: No nothing special. 
Interviewer: Would you use programs that support you in the work with this data? 
Schütz: That depends on the fact whether I loose control over the data. But on the other 
side you have to know that this amounts of data that are stored in my mind were 
growing up with me. So that I think I can handle them. Of course, someone ex-
ternal could have problems with that. 
Interviewer: So you think there is no use for you in using computer based systems? 
Schütz: If I had to look up something more specialized like studies, then it’s a different 
question. In this case I guess it would be helpful because of the huge amount of 
studies. I’m sure you know the PubMed database with all the journals. 
Interviewer: Yes of course. That is a very important topic and we would definitely integrate 
the fields of studies and literature in our research.  
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Schütz: Yes I think that’s the most important part, because it is so complex. The amount 
of data of the patient you have to know is actually very low. And the bench-
marking, means looking for the quality you are producing, for this data there are 
already enough tools. But I think that’s a different topic anyway. In your re-
search you’re not interested in cancer detection and quality assurance, right?   
Interviewer: Actually we’re interested in any kind of data. Our goal is to find ways to visual-
ize this data. That’s definitely not possible for any type of data but we have to 
figure that out. Today there are many ways to do that. 
Schütz: Especially in tumor documentation there is a huge need for such tools. The prob-
lem is that there are already many providers and also national institutions that 
are instructed to develop tumor documentation systems but most of them had to 
understand that this subject is more complex than thought. Also the national cen-
ter of tumor diseases in Heidelberg has promised lots of tumor databases. But 
untill now there isn’t a big number of databases. 
 Switching to Scenario 1. (Appendix A: Scenario 1) 
Giving general information about the interface and the overview page.  
Switching to the population based graph tool.  
 
Schütz: That seems similar to Adjuvant! Online. Which database is it using?  
Interviewer: For the first implementation we’ll use the SEER database, because it’s a huge 
database with ca. 800 000 entries and it’s free available. But the database should 
be easy changeable so that we could use a german database too. 
Schütz: But in germany and also in Europe you don’t have a good all-embracing data-
base. The SEER database represents a huge population that covers everything. In 
germany you don’t have such a population. Only the database which Mr Hölzl 
developed in Munich, but it covers only Bavaria. And that’s already the biggest 
you will find in germany.  
Interviewer: But we talk here about a research project. In this way we’re sometimes thinking 
of hypothetical data and databases. We hope and assume that in the future the 
available data is getting bigger and is covering bigger populations.  
Schütz: Maybe I could put someone in contact with you. A friend of mine is just visiting 
Mr Slamon at the UCLA. Mr Slamon is one of the most famous scientist world-
wide for breast cancer and is researching especially in the field of the epigenetic. 
He is the great star of the oncology and a candidate for the nobel price. This 
friend is managing the mammography screening of the state of california. His 
name is Peter Fasching from Erlangen. He is also statistician and could tell you a 
lot of things to databases and visualizations.  
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 Back to the Scenario and the graph tool. 
Explaining how the survival curves are working. 
Interviewer: Do you see the advantages of this tool for you? 
Schütz: That depends on the tumor entity. It’s very difficult to explain a patient a disas-
trous prognosis. You wouldn’t do that with curves, you would speak with the 
patient and don’t take the last hope. But in the field of breast cancer, if you 
know Adjuvant! Online, I use it to visualize the effects of a therapy in pie charts. 
Similar to your Kaplan Meier Survival Plots. Another benefit is that you can 
display the different therapies and show the patient in which way every therapy 
improves the prognosis. And in this, patients can see that doing a lot, improves 
the prognosis a lot. And at the end you can say that 80% of women are cured if 
they do everything, but still 20% are dying doesn’t matter what we do. And we 
can’t say at which point they are. I think women appreciate this visualizations 
and that’s the important thing. The easier you can do it the better it is. I guess 
that your Kaplan Meier Curves are too complicated for a patient. And someone 
like me who knows a lot of patients and studies, doesn’t need such visualizations 
because I know this curves. And I can calculate this numbers on my own, that’s 
the reason why I don’t use Adjuvant! Online anymore. I can’t do it absolutely 
precisely but that’s not necessary. But I think it could be very helpful for young-
er colleagues and patients.   
Interviewer: You mentioned that the curves are too complicated. In which way would you 
visualize this data? 
Schütz: Yes I guess it’s too complicated in the way you have it in your slides. They only 
differ in the grade or in the age and that isn’t of interest for the patient or the 
physician, because he doesn’t has to know what could have happened if he had 
met the patient earlier. 
Interviewer: But that’s only an example. We would also include other parameters like thera-
pies to show the differences between them.   
Schütz: OK the integration of therapies would be much more of interest. In this case I 
can see the benefits of such a tool. But I would do it more patient oriented. 
That’s very academic.  
I also think it’s very important to look to future technologies as you did it in the 
other Scenario with the pathways or methylations or gene expressions. I’m sure 
that will play an important role in the future. There are already tumor entities 
where it is used, in leukemia for example. Unfortunately not in gynecology but it 
will. The next will be Oncotype DX but it will take another 3-4 years. But I 
think you’re on the right way with these tools. But you have to remember that 
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this amounts of data is not not always connected to each other. As an example 
you have four parallel studies with different gene expressions or methylations 
and each of them is about a different group of patients but never in comparison 
with another study. For example Oncotype DX has never been correlated in 
combination with a unimorphism from type 2D6. This are very special tests and 
shouldn’t be seen additive.  
 So what would you do if Oncotype DX puts the patient into the intermediate risk 
level or into the lowest and another test would put her into the highest risk level?       
Interviewer: That’s true. In this fields a lot of research is needed. But as you said, it will be 
one of the topics in the close future and we’re sure that such tools are also nec-
essary to show the benefits.  
Schütz: Of course. 
And maybe I have another idea. If I’m right you want to show patient or the 
physician with this tool in which risk population the person is. For this you 
could additionally implement the quality of the probe and  the classical risk fac-
tors as you showed in Scenario 1. And then you could make a summary how 
many factors result in a good and how many result in a bad prognosis. 
 Switching to the literature search and the Word Cloud 
Interviewer: Are you interested in such ways of summarizing text? 
Schütz: Oh yes, sure. Definitely a nice add-on.  
Interviewer: What do you currently use for literature searches? PubMed? 
Schütz: Yes. 
Interviewer: The next tool is the search for studies. I learned it’s more difficult in germany 
because there isn’t a all-embracing study register. 
Schütz: That’s right. It would be great to have something like a centralized study register 
but that’s a huge mission. 
Interviewer: In the US there is the webpage clinicalTrials.gov that manages the studies. 
Schütz: Meanwhile we have something similar in Europe called the EOSTC (European 
Organisation for Research and Treatment of Cancer). You have to register every 
study there, because without that you don’t get an Ethics Commission Vote. So 
we already have that correspondingly to clinicalTrials.gov, but in germany itself 
there is no study register or something similar. 
That’s also something that is very annoying for our patients.  
Interviewer: The purpose for this tool is to make a filtered search for the specific parameters 
of our patient and to search for studies in a specific location. So that we only 
find studies that are relevant for the patient. We think that this would be very 
helpful for patients and for their physicians too. 
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Schütz: Yes I think so too. But in germany you have the problem that every physicians 
are a little bit selfish and lazy in connection with studies. So they prefer to keep 
the patient for themselves to earn money. I guess that’s similar in America but 
maybe the patients are a bit more self-sufficient. That was my impression.   
Interviewer: Okay. Maybe we shouldn’t take germany as an example. Another idea we had 
for this tool is the possibility to integrate the results of the studies if available. 
That’s not that important for the patient but we hope that physicians could have 
a benefit of this. 
Schütz: Yes I think that’s a nice idea.  
Interviewer: Okay that was the last tool. Now you have heard a lot of things about our ideas. 
Could you imagine something else that we forgot? 
Schütz: No, not at the moment.  
Your tool that is similar to Adjuvant! Online looks really good and I’m sure it’s 
still possible to optimize it. And if you integrate the studies and I’m sure you 
have the better conditions in America for that, you’re definitely on the right way.  
Interviewer: Finally, can you imagine the advantages of these tools? 
Schütz: Yes of course. Especially for younger physicians. Also the literature search 
seems a nice idea. 
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Appendix C: Second Interviews 
Interview Dr. Clemens Stockklausner - 25.11.10 
 
 Beginning with the presentation of the Visual Query Builder.  
Stockklausner: Would be interesting if we could compare different therapies, as example with 
stem cell transplantation and without stem cell transplantation. If we had a but-
ton: Show data of patients with the same risk strategy with a more intensive 
therapy. And also might break down why the mortality is higher with or with-
out a different therapy. Are they dying from the poison therapy or because the 
tumor is coming back? Does the tumor coming less back because of the more 
intensive therapy or is the result the same since many patients are dying of this 
therapy? And that’s important because patients are asking exactly these ques-
tions. And in this case such a visualization would be helpful. Sometimes we 
have to make decisions at a threshold where you have to decide if you take the 
more intensive therapy with the higher mortality but then this effect must be at 
least compensated by less recurrences.    
Interviewer: So you would use such a tool? 
Stockklausner: Yes I could imagine that.  
You need huge database with information from the literature like Marvin, a 
computer based system. 
I think it’s less important for us because we know these curves but thinking of 
the talks with the patients it would be good. 
As an example I would show a curve with a weaker therapy and with a more 
intensive therapy and then only the recurrences of the tumor. In this case I can 
see that the recurrences is going back. And then I could click on the next screen 
and show the mortality of this therapy. In this way I can see the other side. By 
overlaying both curves I can see the advantages of the more intensive therapy 
for example. In this way I could imagine that.  
 Biological Pathway Visualizer 
Interviewer: Are you using genetic data? 
Stockklausner: Leukemia with BCR-ABL, but I know that there is a antibody. 
Interviewer: What do you think of visualizing pathways in this way? 
Stockklausner: I think there is more use as eLearning or for students and younger physicians, 
that you can click through these pathways.  
That’s not relevant for us since only less genetic influence. 
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 Literature Search 
Stockklausner: That looks good for Leukemia. Because there are many different gene constel-
lations and many new antibodies in research. And you can’t always know all of 
them. But I would need more filters like age groups under 10 and so on. So that 
the results are getting less and more specific.  
Maybe you have to create different filter groups for the different medical 
fields. But that would definitely helpful. 
 Text Summarizing Tools 
Stockklausner: I’m not sure about that. Looks nice but I’m not sure of the use of it. 
 Geographical Trial Finder 
Stockklausner: In germany you have the website Kinderkrebsinfo.de which makes the studies 
in germany available in the field of children oncology. 
But I think it’s less relevant in germany because it is small and easy managea-
ble. In the field of children I can’t see potential benefits. If you would expand it 
to Europe for example then it’s getting more interesting.   
Interviewer: What do you think of integrating the results of the studies into this tool? 
Stockklausner: In the field of children oncology it’s a little bit different. I have one study 
which is representative for whole Europe. If a new type of Leukemia is appear-
ing I can’t choose between study A or B. I see the relevance more in the thera-
py of adults. In this case I have different possibilities and different medical 
centers.   
Interviewer: Do you generally think these tools are useful and would you use them? 
Stockklausner: Yes of course. You can see that others have similar ideas, for example in the 
field of studies. 
I also could think of a good use in semi professional fields, so that parents and 
patients have a good possibility to inform themselves.  
As an example they could look at the pathways to see why exactly they get this 
drug. That could help as an explanation.  
You have also developed a great platform which can be used by interested per-
sons affected or the family doctor who doesn’t has to handle such diseases eve-
ry day.  
From my point of view, it’s my job to have the information when a child with 
Leukemia is coming to us. But the family doctor who has a child with suspi-
cion of Leukemia in his office must look who is responsible for that cancer 
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type. And then he could offer the parents different centers. After that the pa-
tient comes back with the recommendation and drugs. Maybe the patient is 
asking his family doctor why he is getting exactly this antibody and the family 
doctor can teach himself by using these visualizations because that are new 
drugs and people mostly don’t know them. And then he could show this infor-
mation to his patient in a nice visualization. 
It’s unlikely that it’s allowed to make all data available for everyone but you 
could use a login like DocCheck (http://www.doccheck.com/de/) and make the 
different tools available for different types of groups. Creating a private, pass-
word protected area and a public area would address a much bigger range of 
people. 
Actually I think that’s a really good thing if you substantiate the complete thing 
and create different groups. A group with the pathways for us which must be 
always up-to-date and has good filters and a good database as backend, with 
password protected data. The literature search and trials could be public and 
available for everyone. 
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Interview Dr. Jörg Heil 25.11.10 
 
 Beginning with the presentation of the Visual Query Builder.  
Heil: Looks very interesting. 
Interviewer: Do you see the benefits of such a tool in your daily workflow? 
Heil: Yes of course. In this moment the tool shows only the survival probability re-
gardless of the therapy. Only this doesn’t really improves the current procedure.  
It will be more interesting if you can say: What are the benefits of an anti-
hormonal therapy, how does the curve changes. What are the benefits of a chem-
otherapy or maybe different types of chemotherapy. That would be absolutely 
great. 
Of course similar to Adjuvant!Online but much more funded. 
Interviewer: Do you have other ideas of using that data? 
Heil: For the therapy dependency logically.With the background of making things nic-
er, faster and more understandable in the patient talk. Meaning you could present 
curves to the patient which shows what happens statistically if she doesn’t use a 
therapy and what happens if she uses one therapy or another or if she combines 
different therapies.      
Interviewer: That means you see the use of the tool for helping patients to understand and less 
to help you in your decision? 
Heil: Exactly. But that’s an interdependence. If I’m convinced of a therapy decision I 
can explain it to the patient in a better way. That means in cases in which I’m not 
absolutely sure about the effect of a therapy I can make a quick look in that tool 
and see for example: The absolutely benefit is only 3% in the next 5 years. In 
this way you can control yourself sometimes about your feelings and thinkings 
of therapy benefits.   
Only very few physicians can remember all these numbers. And I think the abso-
lutely benefit is overestimated by many of them. 
In this case, personal experiences do not lead to anything. You’re treating maybe 
100 women and have to do post-treatment about 10 years for each of them. 
That’s only a small group of possible cases so most times you have absolutely 
new conditions.  
You can get much better assessments by using studies or using tools like Adju-
vant!Online.       
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 Biological Pathway Visualizer 
Heil: That’s definitely the future. The problem is that our system obliges the use of 
randomized controlled studies. These studies need 5 years until they can even 
begin and again 5 years until you get first results. 
I think until we used genetic data in therapy decisions it will take more than 10 
years because our demands about the evidence is very high.  
 Trastuzumab was the first breakthrough in the anti body therapy nothing but af-
ter that there was more or less nothing. 
Pertuzumab and Avastin and all of them don’t have the breakthrough till now.   
Interviewer: What do you think in general of this idea? 
Heil: If these information are available and you can interfere in a complex pathway 
then it’s very important. Because then the therapy decision gets much more 
complex as it is today and you definitely can’t remember all this data. Impossi-
bly.  
Interviewer: So you don’t use any genetic data at the moment, right? 
Heil: No we don’t. At least not officially. We don’t use it for making decisions but in 
special cases we’re telling the patient the way of the guideline and what we re-
sults we have on genetic side and how it could change the therapy in the next 
years. So she can decide what she want to do. But that’s in the earliest days.  
But first the experiences of the cancer on molecular level must be generated. 
That means we need kits with which you can analyze the patients’ genome in a 
fast and cheap way. And exactly this will be relevant for the clinical practice if it 
can be realized for a wide range.     
 Literature Search 
Heil: PubMed is irrelevant in the clinical practice. Means for patient care because it is 
absolutely guideline oriented and if the guideline can’t be used the decisions will 
be done by using the studies of the center. Of course everybody is using PubMed 
but more for scientific research or if you have a case which is absolutely special. 
I’m not using it for the clinical practice either. Only for scientific research.  
 Summarizing tools 
Heil: Definitely not in clinical practice but to get a general overview about a topic it 
seems very nice. 
 Geographical Trial Finder 
Heil: That looks interesting. Specially for knowing where you can find the trials. 
Interviewer: Do you use studies? 
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Heil: Yes sure but not in the way that I say, okay I have a patient with these criteria, 
there are five fitting studies. You recommend the study which is at you center. I 
think for 90% of patients it is not necessary. There are special situations, mostly 
hopeless cases for which you don’t have a study and in which say: If you really 
want to do something there is a last opportunity.  
Interviewer: At the end, do you have any notes or ideas? 
Heil: I think applicable in closer time will be the survival curves if you connect them 
with the therapies. The pathways are extremely futuristic but not unrealistic. The 
complete thing looks very interesting and I’m excited about the result.   
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Interview Dr. Florian Schütz 30.11.10 
 
 Beginning with the presentation of the Visual Query Builder.  
Interviewer: First impressions of this tool? 
Schütz: I have the data in my mind and don’t need it visualized but if I want to explain 
the benefits of the therapies to a patient, these graphs are very nice. If you make 
it available to family doctors who doesn’t work with this data every day it would 
be helpful. I guess you’re using a similar idea like Adjuvant! Online.  
Interviewer: Do you have ideas what we could change or expand to make it better? 
Schütz: No I think it’s pretty good in this way. 
 Biological Pathway Visualizer 
Schütz: It seems very interesting to me. I think that’s the future. Definitely a very future 
oriented tool but I’m sure it will need five to ten years until it will be of im-
portance.  
 Link to Literature Search 
Schütz: Very nice and very helpful.  
Interviewer: Ideas how to make it better? 
Schütz: No very good in this way. 
 Summarizing tools 
Schütz: I can’t see the use of that tools. 
 Geographical Trial Finder 
Schütz: Great for patients. I often have patients who are calling me and asking whether 
we offer this or that study. I think there is less use for family doctors. Either you 
know where a study is offered or you have your contacts which you can call and 
ask where you find the study. And there are competing studies too. So a breast 
center would usually try to offers studies for every situation but no competing 
studies. That means I don’t have two similar studies with the same patient collec-
tive where one study disturbs another.       
Interviewer: That means you think it’s only of interest for patients? 
Schütz: Yes I think so. Because family doctors normally aren’t interested and not includ-
ed in studies. And physicians usually know the studies or someone else who 
knows them. Although in special cases it could be interesting to find facts about 
substances that are only available in the US or in Swiss for example. As an ex-
ample I have a patient who I referred to America because there she could get a 
therapy in a study which wasn’t available in Europe yet. This study for example 
included foreigners, the same study existed in Britain and this study included 
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only british people. This is a problem you should think of.     
Interviewer: Would it be helpful if we integrated the results of the studies directly into the 
tool? 
Schütz: I don’t know. I think there are already other possibilities. Maybe if it would be a 
very simple thing but it depends on who you want to address. If you want to 
have the experts it’s difficult because most of them have other sources where 
they get this information. If you address the patient it’s possible that you expect 
too much and the family doctor or simply a physician of a different medical field 
would also have difficulties in understanding all the facts. 
I would advise you to create specific tools for the particular situation of the pa-
tient by integrating the different guidelines available in the world. 
So you could show the german guidelines to your specific patient but you can 
also visualize what the american or british would do. Because that’s something 
really difficult to find and you have to skim a lot of sources to get the infor-
mation. That would be great. You would have all advices with one klick. 
Interviewer: Summarizing in short words what do you think is good and what could be better? 
Schütz: What I really like are these nice looking graphs and also the possibility to go 
through different medical scenarios with the help of these tools, especially in 
talks. 
But also the idea of the guidelines sounds great for me and should be realized. 
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Appendix D: JavaScript code for a pathway 
 
var labelType, useGradients, nativeTextSupport, animate, ht; 
 
(function() { 
  var ua = navigator.userAgent, 
      iStuff = ua.match(/iPhone/i) || ua.match(/iPad/i), 
      typeOfCanvas = typeof HTMLCanvasElement, 
      nativeCanvasSupport = (typeOfCanvas == 'object' || typeOfCanvas == 'function'), 
      textSupport = nativeCanvasSupport  
        && (typeof document.createElement('canvas').getContext('2d').fillText == 'function'); 
  //I'm setting this based on the fact that ExCanvas provides text support for IE 
  //and that as of today iPhone/iPad current text support is lame 
  labelType = (!nativeCanvasSupport || (textSupport && !iStuff))? 'Native' : 'HTML'; 
  nativeTextSupport = labelType == 'Native'; 
  useGradients = nativeCanvasSupport; 
  animate = !(iStuff || !nativeCanvasSupport); 
)(); 
 
var Log = { 
  elem: false, 
  write: function(text){ 
    if (!this.elem)  
      this.elem = document.getElementById('log'); 
    this.elem.innerHTML = text; 
    this.elem.style.left = (500 - this.elem.offsetWidth / 2) + 'px'; 
  } 
; 
 
$jit.ST.Plot.NodeTypes.implement({ 
   'round-rect': { 
     'render': function(node, canvas) { 
       var width = node.getData('width'),   
           height = node.getData('height'),   
           pos = this.getAlignedPos(node.pos.getc(true), width, height),   
           posX = pos.x,   
           posY = pos.y, 
           deregulated = node.getData('deregulated'), 
           drug = node.getData('drug');  
        
        var ctx = document.getElementById("infovis-canvas").getContext("2d"); 
        ctx.beginPath(); 
        ctx.moveTo(posX, posY); 
        ctx.quadraticCurveTo(posX-10, posY+(height/2), posX, posY+height); 
        ctx.lineTo(posX+width, posY+height); 
        ctx.quadraticCurveTo(posX+width+10, posY+(height/2), posX+width, posY); 
        ctx.closePath(); 
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        var gradient = ctx.createLinearGradient(posX, posY, posX+width, posY+height); 
        if(drug != 0) 
        { 
         gradient.addColorStop(0, "#7a7d11"); 
         gradient.addColorStop(1, "#f7fc27"); 
        } 
        else if(deregulated == 'true') 
        { 
         gradient.addColorStop(0, "#ff7100"); 
         gradient.addColorStop(1, "#fcc79c");         
        } 
        else 
        { 
         gradient.addColorStop(0, "#15428B"); 
         gradient.addColorStop(1, "#99BBE8"); 
        } 
 
        ctx.fillStyle = gradient; 
        ctx.fill(); 
        ctx.strokeStyle = '#000'; 
        ctx.stroke(); 
         
    
    
 );   
 
function init(){ 
  
    var infovis = document.getElementById('infovis'); 
    var w = infovis.offsetWidth - 50, h = infovis.offsetHeight - 50; 
 
    //init Spacetree 
    ht = new $jit.ST({ 
        //id of the visualization container 
        injectInto: 'infovis', 
         
        //By setting overridable=true, 
        //Node and Edge global properties can be 
        //overriden for each node/edge. 
        Node: { 
            overridable: true, 
            'transform': false, 
            height: 30, 
            width: 60, 
            color: "#00008b", 
            type: 'round-rect' 
, 
         
        Edge: { 
            overridable: true, 
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            lineWidth: 3, 
            dim: 20, 
            type: 'arrow' 
, 
         
     
        offsetY: h/2, 
        levelsToShow: 10, 
        levelDistance: 70, 
        siblingOffset: 30, 
        orientation: 'top', 
        //Change the animation transition type 
        transition: $jit.Trans.Quart.easeInOut, 
        //animation duration (in milliseconds) 
        duration:1000, 
        //Enable zooming and panning 
        //with scrolling and DnD 
        Navigation: { 
          enable: true, 
          //Enable panning events only if we're dragging the empty 
          //canvas (and not a node). 
          panning: 'avoid nodes', 
          zooming: 20 
,    
        Label:{ 
         type: 'HTML', 
         size: 20, 
         color: '#fff'         
, 
        PopUp:{ 
            enable: true,   
            type: 'auto',   
            //add positioning offsets   
            offsetX: 20,   
            offsetY: 20,   
            //implement the onShow method to   
            //add content to the tooltip when a node   
            //is hovered   
            onShow: function(popUp, node, isLeaf, domElement) { 
             if(node.getData('drug') != 0 && node.getData('drug') != ""){ 
               
            var html = "<div class=\"tip-title\">" + node.getData('drug') + 
                 "</div><div class=\"tip-text\"><br> <a href=\"\" on-
click=\"literatureSearch('" + node.getData('drug') + "');\"> search 
for Literature</a></div>";   
              popUp.innerHTML =  html;    
             } 
             else{ 
              popUp.style.display = 'none'; 
             } 
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,   
          //This method is called on DOM label creation. 
          //Use this method to add event handlers and styles to 
          //your node. 
          onCreateLabel: function(label, node){ 
              label.innerHTML = node.name; 
              //set label styles 
              var style = label.style; 
              style.color = node.getLabelData('color'); 
               
              style.textAlign= 'center'; 
              style.paddingTop = '3px'; 
              if(node.getData('drug') != 0) 
              { 
               var width = node.getData('width'),   
               height = node.getData('height'),   
               posX = node.pos.getc(true).x,   
               posY = node.pos.getc(true).y; 
                
               var ctx = document.getElementById("infovis-canvas").getContext("2d"); 
               var gradient = ctx.createLinearGradient(posX, posY, posX+width, posY+height); 
          gradient.addColorStop(0, "#000"); 
          gradient.addColorStop(1, "#fff"); 
               node.setData('$gradient', gradient); 
               style.cursor = 'pointer'; 
       
, 
           
          onPlaceLabel: function(label, node) { 
              var style = label.style;   
              style.width = node.getData('width') + 'px';   
              style.height = node.getData('height') + 'px';               
              style.color = node.getLabelData('color');   
              style.fontSize = node.getLabelData('size') + 'px';   
              style.textAlign= 'center';   
              style.paddingTop = '3px';   
              if(node.getData('drug') != 0) 
              { 
               var width = node.getData('width'),   
               height = node.getData('height'),   
               posX = node.pos.getc(true).x,   
               posY = node.pos.getc(true).y; 
                
               var ctx = document.getElementById("infovis-canvas").getContext("2d"); 
               var gradient = ctx.createLinearGradient(posX, posY, posX+width, posY+height); 
          gradient.addColorStop(0, "#000"); 
          gradient.addColorStop(1, "#fff"); 
               node.setData('$gradient', gradient); 
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               style.cursor = 'pointer'; 
        
   
); 
} 
 
